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B cell Lymphoma 6 (BCL6) and Leukaemia/lymphoma related factor (LRF) are Pok-
proteins over-expressed in some types of Non-Hodgkin lymphoma, such as Diffuse 
large B cell lymphoma (DLBCL) and Follicular lymphoma (FL). 
BCL6 is located on the chromosome 3 in the breakpoint affecting 3q27 band which is 
the most frequent translocation in Non-Hodgkin’s lymphomas. This gene is a 
transcription repressor whose principal effect, in human B cell, is to thwart the 
response to DNA damage by inhibiting both a p53-dependent and a MIZ-1 dependent 
pathway. In the germinal centre BCL6 is constitutively expressed to suppress the p53 
action. In B-cell lines BCL6 prevents apoptosis induced by DNA damage. 
LRF, encoded by the Zbtb7a gene, is also known as Pokemon and it is a transcription 
repressor involved in many cellular processes as differentiation, inflammation and 
oncogenesis. LRF indirectly controls p53, acting through p14 and MDM2 repression, 
and it also plays an important role as protooncogene in Non-Hodgkin's lymphomas. 
Both BCL6 and LRF repression act at transcriptional level on the target genes to 
regulate protein expression.  
It has been demonstrated microRNAs, a class of endogenous 22-25 nt single stranded 
RNA molecules, work to regulate target gene expression at post-transcriptional level. 
In fact, these molecules share a partial complementarity with 3’UTR region of 
expressed genes and act repressing translation.  
In this project we focused our attention on the possible correlation between BCL6 and 
LRF over-expression in cell lines derived from Non- Hodgkin's lymphomas. 
Since miRNAs play an important role in tumours and in regulatory circuits in which 
are involved, we focused our attention on the behaviour of the miRNAs belonging to 
the hypothetical circuit that correlates BCL6 and LRF. Using our data and the data 
taken from the literature demonstrated in different model systems, we reconstructed a 
hypothetical circuit connecting BCL6 and LRF to each other. A negative feed back 
loop should link BCL6 and LRF (following the interaction showed in the circuit),  
while in Non-Hodgkin's lymphomas these two genes are found both over-expressed. 
We hypothesized that this double increase could be involved in the high proliferation 
rate typical of tumor cells. The BCL6-LRF network is very intriguing because there are 
transcription factors and miRNAs: both are described as fundamental actors in the 
regulation of the cell cycle, often deregulated in tumours and all are fundamental in the 
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cellular response to stimuli. We treated the Dohh2, a cell line derived from a Non-
Hodgkin's lymphomas, with etoposide, a chemotherapeutic agent, that is able to reduce 
BCL6. We observed that in this condition the Dohh2 cells are not able to proliferate. 
We focused our attention on the circuit and in particular on the behaviour of the 
molecules belonging to it. We noticed that there is an over-expression of miR-145. It is 
interesting because it has been described as a tumour suppressor miRNA and it is under 
p53 control. This transcriptional factor is under BCL6 direct control and LRF indirect 
control. We decided to over-express miR-145 through transient transfection to try to 
reproduce the effect of etoposide. We analyzed the network 24 hours after transfection: 
the transcription factors and miRNAs on the pathway, that hypothetically connects 
BCL6 and LRF, were influenced by the transfection but we did not find any change in 
the proliferation rate of Dohh2 cells. We hypothesized that it was due to the fact the 
over-expression was not sufficiently long. So we tried to prolong the increased 
expression level of miR-145 in Dohh2 cells. We performed a preliminary analysis of 
the circuit in a population stably silenced for BCL6 in which we had a prolonged 
down-regulation of BCL6: in this case the molecules belonging to BCL6-LRF circuit 
were modified too but the proliferation did no change. We focused on the possible 
differences between the etoposide treatment and the others. We noticed that in the 
former there was not only BCL6 and LRF decrease but also miR-145 up-regulation 
accompanied by p53 and E2F1 increase, not present in the other treatments. We can 
hypothesize that the BCL6 and LRF down-regulation are necessary, together with the 
increase of miR-145, p53 and E2F1, to affect proliferation in Dohh2 cells.  
We hypothesized that the alteration of the correlation between BCL6 and LRF could 
have been developed in lymphoma cells in order to increase their proliferation and 
escape from apoptosis or cell death. 
 
 
 
 
  
10 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  
11 
 
The main dogma of genetics was that information flows from DNA to RNA and after 
this from RNA to proteins. The researchers focused their attention on DNA, as a 
molecule that hosts the information of life, and afterwards on proteins considered as 
effectors of such information. The RNA molecules were considered as simple tools of 
connection between them. In the past few years RNA molecules were greatly 
reassessed: they are not just a linker between the information (DNA) and its application 
(proteins), but they represent a complex regulatory system that we started to understand 
only twenty years ago. In fact in the past 20 years researchers found out that the larger 
part of DNA is noncoding RNAs: in highly developed organisms, about 97% of the 
transcription output is represented by noncoding RNAs. This large group of noncoding 
RNAs can be divided into two sub-groups: one of housekeeping RNAs and the other 
regulatory RNAs. In the first group there are for example molecules such as transfer 
RNA (tRNAs), small nuclear RNA (snRNA), ecc.. In the second one there are short-
interfering RNAs (siRNAs), piwi-interacting RNAs (piRNAs), 21U-RNAs and 
microRNAs (miRNAs) (Table n.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table n.1 Comparison between different small RNA species. 
(Modified from International Journal of Biological Sciences. Qazi Mohd. 
Rizwanul Haq, 2009.) 
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siRNAs and miRNAs are present both in plants and animals while piRNAs and 21-U 
RNAs have been described so far as limited to animals. Initially the short RNAs were 
considered a product derived from the degradation of larger molecules. Starting from 
1993 with the lin-4 discovery of Ambros and co-workers in Caenorhabditis elegans as 
an endogenous regulator of genes that control developmental timing a new field of 
science started1. Today it is known that these molecules are involved in the control of 
genes and genomes: in fact, they were described as able to regulate chromatin structure, 
chromosome segregation, transcription, RNA processing, RNA stability, and 
translation. This discovery explained one of the strangest issues of biology: the 
redundancy of DNA and the presence of the junk DNA in the genome. In fact this 
explains the usage of genome and the number of genes present, but it has also 
complicated the situation in terms of biochemical attributes and functional genesis of 
the molecules. These small molecules seem to be present in all kingdoms: from 
unicellular alga Chlamydomonas reinhardtii to humans2,3. These regulatory molecules 
seem also to be present in the prokaryotic world: bacterial short regulatory RNAs have 
also been referred to as small RNAs, but they are not related to eukaryotic small RNAs. 
In fact bacteria have few proteins the domains of which are similar to proteins 
belonging to the RNA interference pathway. Their genome shows sequences of a 
parasite genome called clustered regularly interspaced short palindromic repeats 
(CRISPR). These are multiple noncontiguous direct repeats with spacer sequences and 
make bacteria resistant to phages through the RNA interference pathway: this is a sort 
of primordial immuno system against them4,5. Unfortunately, it is not known how these 
sequences work. 
 
 
1. Short-interfering RNAs (siRNAs) 
 
Short-interfering RNAs (siRNAs) are ~20-24 nt long RNA molecules acting as a 
primitive immune system protecting cells from intrusion of any exogenous nucleic 
acid, as for example viruses, and that are involved in maintaining genome integrity by 
stopping the transcription of retrotransposon and repeat sequences. They move from a 
cell to the other through the phloem, the vascular system of plants6. They are 
characterized by the perfect match between the siRNA and its target RNA. This perfect 
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complementarily is necessary for the recognition of the target. siRNAs are transcribed 
through the RNA dependent RNA polymerase (RdRP) activity on aberrant transcripts 
or transcript with full or partial complementarity 7. RdRP is present in plants, fungi and 
Caenorhabditis elegans, but not in humans7. The main function of this enzyme is the 
generation of secondary siRNAs, a step termed signal amplification in siRNA 
pathway7. RdRP can recognize aberrant RNA molecules to produce dsRNAs either in a 
primer dependent or in an independent manner. In the nucleus siRNAs are processed 
by Dicer, a RNaseIII type endonuclease, that cut the molecules to their characteristic 
length. Animals own one type of this enzyme. The exceptions are represented by 
Drosophila and C. elegans, each encoding two Dicers, while the plants have many of 
them8. Some researches have demonstrated that the presence of many Dicers is 
redundant: each enzyme is dedicated to the processing of a specific type of siRNA, but 
when one Dicer is mutated, its activity is partially taken over by the others9,10. The 
siRNA-Dicer complex is then exported to cytoplasm where it binds to the Argonaute 
proteins. The functions of this family of proteins are mostly unknown: Ago-2 is one of 
the most important members in the siRNAs pathway in plants. Argonaute proteins 
unwind the double strand of RNA: the process starts from the end with lower thermal 
energy. One of the two strands, the passenger strand, is degraded by exonucleases and 
the other, the guide strand, remains in the RISC complex. This complex binds with a 
perfect match to the RNA target and it cuts at the position between the 10 and 11 nt 
from the 5′ end of the siRNA. siRNAs are divided into different classes: trans-acting 
short interfering RNAs (tasiRNA), repeat-associated short interfering RNAs (rasi-
RNAs), scan RNA (scn RNA), long siRNAs (lsiRNAs). 
 Trans-acting short interfering RNAs (tasiRNA) are like miRNAs: they are about 
21 nt long small RNAs that require endogenous transcript as a template and they 
do not have a perfect match with their targets11,12. They cut an endogenous 
mRNA, but the target gene is different from the one originating the siRNA7. 
They are not present in humans because they do not have the RdRP enzyme that 
transcribes the double strand of RNA13. They work against possible erroneous 
transcription to preserve cells7.  
 Repeat-associated short interfering RNAs (rasi-RNAs) are longer than the 
previous class of si-RNA: 24-26 nt. They need the amplification step of the 
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RdRP enzyme. They are important during gametogenesis in flies, worms and 
mammals to regulate the chromatin status, silencing viral transcripts by 
recruiting histone modifying proteins14-17. 
 Scan RNA (scn RNA) are relatively long, about 29 nt and they are described in 
the Tetrahymena thermophila. These protozoans have two nuclei and during the 
conjugation the sncRNA of the micronucleus eliminates the corresponding loci 
from its own genome: this produces the macro-nucleus18,19. 
 Long siRNAs (lsiRNAs) were discovered in Arabidopsis and they are longer 
RNA molecules : 30-40 nt. They are produced in response to bacterial infection 
and growth conditions20.  
 
2. Piwi-interacting RNAs (piRNAs) 
Piwi-interacting RNAs (piRNAs) were divided into two categories depending on their 
length: 24-28 nt and 29-31 nt. These kinds of molecules are specific to germline cells21-
24. In fact, the Argonauta protein family was divided into two sub-groups through 
studies on amino acid sequences: the AGOs, that are present in all cells and that bind to 
all kinds of small RNAs, and the PIWI (P element-induced wimpy testes) that are 
germline-specific25-27. The main part of piRNAs were mapped in the genomic regions 
previously thought to be non-transcribed, while others are found in intergenic, exonic, 
intronic and repeat regions16,23. Generally the transcription of these molecules follows 
an unknown mechanism started by a mono- or bidirectional promoter. It seems that the 
biogenesis of piRNAs does not depend on Dicer action. Unlike the others small RNA 
molecules, it is thought that piRNAs can promote the stability of their mRNA target 
and enhance translation18.  
 
3. 21U-RNAs 
21U-RNAs were identified so far only in C. elegans, C. briggsae28. They are 
characterized by their sequence: 21 nt long with uridine at its 5' end. The majority were 
mapped within intergenic or intronic regions and probably they play a role in chromatin 
reorganization and genome stability since their sequences have no homology with any 
transcript.  
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4. microRNAs 
microRNAs (miRNAs) are a very large family of molecules that were described in 
literature for the first time in 1981 by Ambros and Ruvkun and their collaborators in a 
study about loss of function in Caenorhabditis elegans29. They found that the gene lin-
4 originates two different RNA molecules: a long molecule of around 61 nt and a 
smaller one of around 22 nt1, where by the first is the precursor of the second; the latter 
is required to inhibit the expression of lin-14 messenger and this small RNA is able to 
down-regulate it during the transition from the first to the second larval stage of 
development in the worm C.elegans30,31. In fact, it recognizes complementary sites in 
the 3' untranslated region (3'UTR) of this mRNA target. Moreover it was demonstrated 
that the same lin-4 is able to regulate lin-28 at a later stage of development32. 
Nowadays it is known that miRNAs are a class of endogenous 22-25nt single-strand 
RNA molecules that regulate gene expression at the post-transcriptional level33,34. 
miRNAs are involved in the most varied processes: from the control of leaf and flower 
development in plants35 to pluripotency of embryonic stem cells36,37, from cells 
proliferation to cells death38, from neuronal patterning in nematodes to cancer34. This 
strategy of translational control represents a very fine tuning process which is very 
rapid and not very expensive in the economy of cell energy. This hypothesis is 
supported by the fact that this kind of regulatory system has evolved in different 
kingdoms in an apparently independent way33,39. In fact, miRNAs genes represent the 
largest class of regulatory molecules since they represent 1% of total coding genes40,41.   
 
4.1 miRNAs classification 
In 2003 Sam Griffiths-Jones established at Welcome Trust’s Sanger Institute a miRNA 
register in which all miRNAs discovered are annotated42. The miRNA Registry 
provides a service for the assignment of miRNA gene names prior to publication. This 
is a database of published miRNA sequences that are accessible via a web interface and 
all sequences and annotation data are freely available for download. The classification 
is standard: mammalian miRNA genes are distinguished by the prefix miR- followed 
by a number; while in the miRNA genes of C.elegans the prefix is lin- or let- 43. 
Moreover miRNAs that are transcribed from different loci but showing the same 
sequence are noted under the same name but with a different suffix ( e.g. miR-16-1, 
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miR-16-2), whereas two miRNAs that have one or two different bases  are recorded 
with the same number but with a different letter ( e.g. miR-16a e miR-16b). The less 
represented form of miRNAs in the cells is marked with * (e.g. miR.9*). miRNAs 
having the same seed are clustered in a family because the perfect pairing between 7 
bases of miRNAs's seed and the locus on the 3'UTR of the mRNA target (seed match) 
is the main rule to match the mRNA target44,45. In the remaining pairing between 
miRNA and mRNA mismatch, bubbles, non conventional pairing (as G-U) are 
allowed, even if other pairings (out of the seed match) in an other part of mRNA make 
the match stronger and the repression more efficient46,47. A mRNA can have more seed 
matches for the same or different miRNA, which can produce a synergic action of 
repression on mRNA of miRNAs32,48-51. A candidate gene to be annotated as novel 
miRNA must have the following characteristics: the first criterion (expression) plus the 
second criterion (structure), or the first criterion (expression) plus the third criterion 
(conservation).  
 
4.2 miRNAs localization 
miRNAs can be localized in different parts of genome: they can be categorized 
according to their genomic locations relative to exon and intron positions (Fig. 1)52-55. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of primary microRNA transcripts (pri-miRNAs). miRNA 
host transcripts may be unspliced, or miRNAs may be located within introns, exons, 
or untranslated regions (UTRs) of spliced transcripts (Modified from Mendell ,Cell 
Cycle 2005).  
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In fact the miR-985 hairpin is found in the last exon of CACNG8 mRNA a protein-
coding transcript56, but it is well known that more than 80% of miRNAs are localized 
in introns of genes that codify or do not codify for proteins (Fig. 2)54.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic diagram to depict differences between mirtron and 
canonical miRNA generation. Introns that assume foldback structures are 
recognized and cleaved by DROSHA. These stem-loop lariats are then acted upon 
by Lariat debranching enzyme that cleaves the phospho-diester bond formed during 
the splicing event. The primiR thus formed joins the mainstream miRNA flux, 
before making exit to cytoplasm (Modified from Rizwanul Haq. International 
Journal of Biological Sciences 2009). 
 
These miRNAs are called mirtrons, for example miR-106b, miR-93 and miR-25 that 
are localized in introns of the gene that codifies for protein mcm-757. When miRNAs 
are found in introns their expression profile follows that of the gene in which they are 
localized: after transcription mRNA undergoes splicing and miRNAs are 
processed53,58,59. Introns are characterized by flanking regions in which conserved 
nucleotide sequences, for example GU-AG, are present. They are recognized by the 
proteins removing the intron. This sequence folds in a lariat with a typical 2'-5' 
phosphodiester bond that is performed by Lariat debranching enzyme that cleaves it60. 
Mirtrons do not need DROSHA/DGCR8 maturation: they can leave the nucleus 
through the Exportin-5 after the action of Lariat debranching enzyme. The mirtrons 
have not been identified in plants and other organisms yet. Since the introns are not 
subjected to selective pressure it is logical to assume that they are unlikely to preserve 
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their sequences and this could explain their specificity. Other miRNAs are localized in 
introns or exons of genes that do not codify for proteins. For example the miR-15a and 
miR-16-1 cluster is found in the intron of a well-defined non-coding RNA gene, 
DLEU261, or the miR-155 is located in BIC: a previously defined non-coding RNA 
gene. All these miRNAs can be orientated in a sense or non-sense with respect to the 
gene in which they are found58. 30% of miRNAs have an independent origin of 
transcription44,62,63. In the literature there are examples of the same miRNA that is 
transcribed on a different chromosome: the precursor miR-1 is miR-1-1 that is 
expressed in the atrium of heart during the embryonic development of mouse while 
miR-1-2 is expressed in the ventricle64. Similar examples are miR-30c-1 and miR-30c-
265. The action of miRNAs plays in trans: they target a mRNA transcribed from a gene 
located in another part of DNA. They can be grouped in a cluster and in this case 
scientists have supposed that they are expressed together and if they belong to the same 
family they have probably originated from a tandem duplication66-68. Approximately 
50% of mammalian miRNA loci are found near to other miRNAs. These clustered 
miRNAs are transcribed from a single polycistronic transcription unit. miRNAs 
belonging to different families could also be present in a same cluster: they may be 
involved in the regulation of genes related each others. A transcript may encode 
clusters of distinct miRNAs, or it may encode a miRNA and messenger . 
 
4.3 Biogenesis: miRNAs Transcription 
miRNAs's biogenesis is effected by diverse enzymes in different subcellular 
compartments. In fact maturation occurs through sequential processing events: 
miRNAs are first transcribed as a large RNA molecule, termed a primary miRNA (pri-
miRNA), which is sequentially processed in the nucleus, to give the approximately 65-
nt pre-miRNA hairpin intermediate, and then in the cytoplasm, to give the mature 
miRNA (Fig. 3). A pri-miRNA hallmark is the stem-loop hairpin where imperfect 
pairings in the stem take place63. In the lower part of harping there are flanking 
sequences that are important for the following step of miRNA's maturation.  
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Most miRNAs are located in intergenic regions (>1 kb away from annotated/predicted 
genes), although a sizeable minority was found in the intronic regions of known genes 
in the sense or antisense orientation. miRNA genes can be transcribed from their own 
promoters, and the clustered miRNAs are generated as polycistronic primary transcripts 
(pri-miRNAs). Transcription of miRNA genes is mediated by RNA polymerase II (pol 
II)54,66,69,70 a minor group of miRNAs that are associated with Alu repeats can be 
transcribed by Pol III 71. Furthermore, chromatin immunoprecipitation analysis shows 
that pol II is physically associated with a miRNA promoter66. miRNA gene 
Figure 3. MicroRNA biogenesis. pri-miRNA, transcribed by polII, are processed 
by Drosha in the nucleus. Pre-miRNAs undergo cytoplasmic translocation, which 
is mediated by exportin 5 in conjunction with Ran-GTP, and are subsequently 
processed into RNA duplexes of about 22 nucleotides by Dicer. The RISC-
miRNA complex is guided to the mRNA target for translational repression or 
degradation (Modified from Kim, Nature 2005).  
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transcription can be controlled by various pol-II-associated regulatory factors, so that a 
specific set of miRNAs can be expressed during development as well as under specific 
conditions and in certain cell types34. In addition, the expression of miRNA and 
protein-coding genes might be coordinated, especially when a miRNA and a protein- 
coding region both reside in a single transcript. miRNAs can have their own promoter 
as for example let-7 in C.elegans that depends on an element enhancer called TRE 
(Temporal Regulatory Element) that is located at about 1200 bp upstream of the mature 
miRNA72. From the literature it is well known that there are transcription factors able 
to transcribe some miRNAs independently as for example miR-1 that is transcribed by 
Serum Response Factor (SRF)64 or cluster miR-17 that is transcribed by c-Myc73. The 
primary miRNA transcript (pri-miRNAs) contains a cap structure as well as a poly(A) 
tail, which are the unique properties of class II gene transcripts66,69,74,75.  
 
4.4 From pri-miRNA to pre-miRNA 
Pri-miRNA undergoes a first processing in the nucleus by means of an enzyme called 
Drosha76: a RNase III protein of about 160 kDa that is well conserved in the animal 
kingdom77-79. The stem-loop structure is cleaved by the nuclear RNase III Drosha to 
release the precursor of miRNA (pre-miRNA). The remnants, the flanking fragments, 
are thought to be degraded in the nucleus. Drosha contains two tandem RNase III 
domains (RIIIDs) and a double-stranded RNA-binding domain (dsRBD) that are 
crucial for catalysis (Fig. 4)80,81.  
 
 
 
 
 
 
Figure 4. Domain Organization of Human Drosha. RIII, RNase III catalytic 
domain; D, dsRNA binding domain; PRORICH, proline-rich domain; RS-RICH, 
arginine/serine rich domain (Modified from Bryan R. Cullen. Molecular Cell,2004). 
 
 
The central region of the protein, adjacent to the RIIIDs, is also essential for pri-
miRNA processing. RNase III are divided into three different classes: first class 
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enzymes are found in bacteria and in yeast and they have one side of binding at double 
RNA strand and one domain  RNase  III82. Enzymes of class II and III instead have a 
helicasic domain and a Paz (Piwi/ Argonaute/ Zwille) domain that is typical for 
Argonaute proteins. Drosha is RNasi III enzyme of II class. Drosha forms a large 
complex of ~500 kDa in D. melanogaster83 or ~650 kDa in humans82,84 called 
Microprocessor complex. In this complex Drosha interacts with a cofactor: the 
DiGeorge syndrome critical region gene 8 (DGCR8) protein in humans (also known as 
Pasha in D. melanogaster and C. elegans). When DGCR8 protein is mutated in humans 
it causes the DiGeorge syndrome, provoking specific heart malformations, facial 
malformations, anomaly of the endocrine and immune systems84. DGCR8/Pasha is a 
~120 kDa protein that contains two dsRBDs83. It also contains a putative WW domain, 
which is known to be an interaction module for specific proline-rich sequences. It 
remains to be determined if this domain interacts with the proline rich region of 
Drosha. Although the biochemical role of DGCR8/Pasha is currently unclear, it is 
believed to assist Drosha in substrate recognition. Through interaction with DGCR8, 
Drosha cuts dsRNA to create a 5' phosphate and 2 nt 3' loops currently used to define 
miRNA 85(Fig. 5). This product is called pre-miRNA and its protruding end is 
important for the following step of processing. Drosha depends upon its protein 
cofactor for the efficiency and accuracy of this processing (see below). This enzyme 
can cleave not only pri-miRNAs but also mRNAs that contain long hairpins. Drosha 
negatively regulates its own cofactor, DGCR8, by cleaving the hairpins in the second 
exon of the DGCR8 mRNA86. The introns containing miRNA are spliced more slowly 
than the adjacent introns for unknown reasons. The splicing commitment complex is 
thought to tether the introns ( exon-tethering model) while Drosha cleaves the miRNA 
hairpin87. The pre-miRNA enters the miRNA pathway, while the rest of the transcript 
undergoes pre-mRNA splicing and produces mature mRNA for protein synthesis. 
Another way the miRNAs located in the introns are processed is bypassing the Drosha 
step. The mRNA is spliced and the intron is debranched. The mirtrons show similar 
protruding ends. Sometimes some pri-miRNAs are edited by Adenosine Deaminase 
Acting on RNA (ADARs) at specific positions (generally +4 and +44) changing 
adenine to inosine88,89. This process increases the variability of miRNAs in the cells. 
After this passage these molecules are also processed by Drosha. 
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4.5 Nuclear export by exportin-5 
Nuclear export of pre-miRNAs is a crucial step in miRNA biogenesis: pre-miRNA is 
actively transported from the nucleus to the cytoplasm by Ran-GTP and the export 
receptor Exportin-5. Members of the nuclear export receptor family bind cooperatively 
to the cargo as well as to the GTP bound form of the cofactor Ran (RAS-related 
nuclear protein) in the nucleus (Fig. 6)90-93.  
Following export, hydrolysis of GTP to GDP results in the release of the cargo from 
the export complex. A structural motif can be found in pre-miRNA stem-loops, which 
typically comprise a stem of ~22 bp, a terminal loop and a 3′ overhang of ~2 
nucleotides. By introducing mutations in the pre-miR-30a, Cullen and colleagues 
confirmed that a RNA stem of >16 bp and a short 3′ overhang are significant structural 
requirements for pre-miRNA export34,94. 
 
 
 
 
 
Figure 5. Drosha/pri-miRNA complex. Drosha, interacting with DGCR8 
cuts the ends at the lower part of pri-miRNA ( Modified from Kim, Nature 
2005).  
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Figure 6. Pre-miRNA transit from the nucleus to cytoplasm. Pre-miRNA is a 
transport complex together with exportin-5 and its cofactor Ran (the GTP-bound 
form) ( Modified from Kim, 2005 Nature). 
 
 
4.6 From pre-miRNA to miRNA 
When pre-miRNA arrives in the citosol it undergoes another transformation performed 
by another endonuclease: Dicer95-98. This is an enzyme of 160 kDa, a highly conserved 
RNase III which is well conserved in eukaryotes (Fig. 7).  
 
 
 
 
 
Figure 7. Domain Organization of Human Dicer. Helicase and Paz domain; RIII, 
RNase III catalytic domain; D, dsRNA binding domain. (Modified from Bryan R. 
Cullen. Molecular Cell, 2004) 
 
Dicer joins with other proteins of the Argonaute family to stabilize pre-miRNAs99,100. 
D. melanogaster Dicer 1 requires Loquacious, which contains three dsRNA-binding 
domains (dsRBDs) for pre-miRNA processing101.Three splice variants of Loquacious 
are known, of which only two isoforms interact with Dicer-1. Interestingly, the third 
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isoform lacks the non-canonical dsRBD, suggesting that this domain may be essential 
for association with Dicer-1102. Loquacious plays a critical role in the maintenance of 
germ-line stem cells: mutant female flies are sterile and lack germ-line stem cells103. 
Human Dicer interacts with two closely related proteins, TRBP (TAR RNA-binding 
protein; also known as TARBP2)104,105 and PACT (also known as PRKRA)106. So far 
the biochemical role of these proteins is unclear: neither is required for processing 
activity itself. They seem to contribute to formation of the RNA-induced silencing 
complex. In addition to the binding site for double stranded RNA on Dicer there are 
catalytic sites that perform the cut to generate the new miRNA end. Dicer, through the 
Paz domain, recognizes the end cuts by Drosha and binds pre-miRNA, but the reaction 
centre lies in the RNase III domains107. Each of the two RNase III active sites cleaves 
one of the two strands, leading to a staggered duplex scission to generate new ends 
with 2 nt 3′ overhangs. The reaction leaves a 5′ monophosphate on the product end and 
2 nt overhang at 3' (Fig. 8)108. This 5’ monophospate is later required for loop removal.  
 
 
 
 
 
 
 
 
 
 
 
Figure. 8. Dicer/pre-miRNA complex. Dicer interacting with pre-miRNA takes 
off removes the loop (Modified from Kim, Nature 2005).  
 
Dicer releases a double strand of RNA with imperfect pairing. Some organisms, 
including mammals and nematodes, have only a single Dicer that does double duty in 
the biogenesis of both miRNAs and siRNAs, whereas other organisms divide this task 
among multiple Dicer proteins101. After the Dicer action has taken place the double 
RNA molecules are loaded in a multiprotein complex called RNA induced silencing 
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complex (RISC)109-114. Argonaute proteins are the core of this complex. They are 
characterized by four domains: the N-terminal (N), the PAZ domain, that is common in 
Dicer, the PIWI domain that is unique to the Argonaute family115, and middle (Mid) 
domains. The Argonaute PAZ domain has RNA 3′ terminus binding activity, and the 
5′-phosphate engages pocket in the Mid domain. 
When this miRNA-RISC complex is formed, the RNA duplex is unwound, based on 
thermodynamic stability of the duplex's ends116. In mammals, miRNAs having nuclear 
signal sequences can traffic back to the nucleus where they can target many under-
processed transcripts or bring about silencing of genomic regions. 
 
4.7 Action of miRNA 
miRNA is the guide for the  identification of mRNA  by  the RISC complex. The main 
rule is the almost perfect match between the seed on seven nt of miRNA, included 
between its second and eighth base (miRNA seed), and the seed match on mRNA 
target (Fig. 9)31,32,46,117-120.  
 
 
 
 
 
 
Figure 9. miRNA recognition of target mRNAs. A lin-4 binding site in the 3’ 
UTR of lin-14 is depicted to illustrate typical features of miRNA:target interactions. 
In the figure the perfect match that occurs in the seed region is shown. (Modified 
from Mendell ,Cell Cycle 2005).  
 
 
 
 
Out of the seed some mismatches are allowed in animals, while in plants the binding is 
near-perfect. The complex miRNA-RISC-mRNA moves to particular foci in the citosol 
called Processing bodies (P-bodies) or GW-bodies (Fig. 10)121,122. 
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Figure 10. mRNA processing in P-bodies. mRNA linked with one or more 
miRNAs in the P-bodies can undergo repression of translation or degradation 
(Modified from Zamore, Science 2005 ). 
 
 
In fact, the GW-182 protein is one of most abundant protein in P-bodies and when it is 
silenced through si-RNA the researchers observed these foci failed to assemble121,122. 
Similar structures were discovered in plants where they are called Cajal bodies123. 
These are a kind of storage sites for translationally suppressed mRNAs that are released 
when required and can actively translate into the nucleus. If the match between the 
miRNA and its target is perfect scission of the mRNA occurs. An example of this 
action is represented by the miR-196a that degrades HOXB8 transcript 124,125. Instead, 
if the binding presents mismatches there is repression of translation by unexplained 
mechanisms. 
According to a proposed model there is competition between miRISC and eIF4E for 
binding to the mRNA 5′ cap structure (Fig. 11)74,75,126,127.  
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Figure 11. Possible mechanisms of miRNA’s repression. Non-repressed mRNAs 
recruit initiation factors and ribosomal subunits and form circularized structures that 
enhance translation (a). When miRISCs bind to mRNAs, they can repress initiation 
at the cap recognition stage (b) or the 60S recruitment stage (c). Alternatively, they 
can induce deadenylation of the mRNA and thereby inhibit circularization of the 
mRNA (d). They can also repress a post-initiation stage of translation by inducing 
ribosomes to drop off prematurely (e). Finally, they can promote mRNA 
degradation by inducing deadenylation followed by decapping (f) (Modified from 
Erik J. Sontheimer. Cell. 2009). 
 
 
eIF4E is a sub-unit of eIF4F complex that starts the translation. eIF4E binds the 
methylated base of the cap between two tryptophan residues. The Mid domain of 
human Ago2, with two phenylalanine residues, is hypothesized to compete with eIF4E. 
A second model suggests miRISC should promote deadenylation of the mRNA tail. 
The cap and PABP1-free tail of the deadenylated mRNA are unable to circularize so 
translation is repressed128-131.  
A third model proposes that miRISC blocks association of the 60S ribosomal subunit 
with the 40S pre-initiation complex. Human AGO2 binds eIF6 and 60S ribosomal 
subunits in vitro and eIF6 is involved in the biogenesis and the maturation of 60S 
ribosomal subunits, thus preventing their binding with 40S subunits132. 
a 
b 
c 
d 
e 
f 
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But all these models present some contradictions and none has the capability of  
explaining the action of miRNAs completely. 
 
 4.8 miRNAs and cancer 
Cancer is one of the most common diseases in the world: cancer-related global 
mortality follows only cardiovascular and infectious illnesses133. Tumors are a class of 
disease affecting people at all ages and also animals. The sickness is caused by hyper 
proliferation and an inappropriate survival of damaged cells that are not controlled by 
normal cell signals. These cells are able to grow beyond normal limits: they are capable 
of metastasizing, invading and colonizing other tissues in the body. There are many 
causes for the onset of cancer: exposure to carcinogens, genetic errors in the DNA 
replication, inheritance or chance. Tumor suppressor genes are inactivated in cancer 
cells, resulting in the loss of normal functions, such as accurate DNA replication, 
control over the cell cycle, orientation and adhesion within tissues, and interaction with 
protective cells of the immune system. Oncogenes are typically activated in cancer 
cells, giving them some advantages, such as faster growth and division, protection 
against programmed cell death, the ability to form metastases. A new large class of 
molecules that is important in these kinds of disease are microRNAs (Table n.2)134. The 
first evidence of aberrant miRNA expression in human cancers was described in B-cell 
chronic lymphocytic leukaemia. In this illness the loss or reduction of miR-15 and 
miR-16 expression was found, which causes the B-cell chronic lymphocytic 
leukaemia61. There is other evidence in this direction, as for example the over-
expression of miR-17-92 cluster, located at chromosome 13q31, a region that is 
amplified in B-cell lymphomas135. 
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Table 2. Oncogenic or tumor-suppressive miRNAs and their direct target 
genes (Modified from Anindya Dutta The Annual Review of Pathology 2009) 
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Post translational modifications of miRNAs, as for example methylation, could cause 
the tumour formation. In fact, a wrong miRNA gene methylation could bring about the 
deregulation of their expression in cells136. Moreover in human genome many miRNAs 
Figure 12. miRNA oncogenes and tumour suppressors. (a) Reduced miRNA 
levels, reflecting defects at any stage of miRNA biogenesis (indicated by 
question marks), produce inappropriate expression of target oncoproteins (purple 
squares). The resulting defects in homeostasis increase proliferation, invasiveness 
or angiogenesis, or decrease the levels of apoptosis or differentiation, 
potentiating tumour formation. (b) Conversely, over-expression of an oncogenic 
miRNA eliminates the expression of tumour-suppressor genes (pink), leading to 
cancer progression (Modified from Slack FJ Nature review 2006). 
 
 
 
a                                                      b 
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are located at fragile sites, which in particular types of tumour, are associated with 
DNA rearrangements suggesting a correlation between miRNAs and cancer137. Another 
case in which a defect in the miRNA biogenesis machinery can produce the 
deregulation of miRNAs and as consequently the tumour formation if this miRNA has 
a tumour gene or a tumour suppressor gene as a target.138,139. It can be affirmed that 
miRNAs can act as tumour suppressors and oncogenes (Fig.12)134,137,140-146. Tumour 
suppressor miRNAs can target an oncogene stimulating apoptosis of cells or inhibiting 
cell proliferation. On the contrary, miRNAs that negatively regulate tumour-suppressor 
genes for example by stimulating cell proliferation and inhibiting apoptosis act as 
oncogenes. miRNAs could promote the tumour formation also by affecting the proteins 
involved in the cell cycle. For example miR-221 and miR-222, that are over-expressed 
in many tumours, are able to target p27 and p57 mRNAs147,148. These two proteins are 
two negative cell-cycle regulators: they bind to Cdk/cyclin complexes and inhibit the 
G1/S phase switch. miRNAs are involved not only in tumour formation but also in its 
diffusion. In fact, miR-10 was demonstrated to promote metastases in breast cancer 
cells. This miRNA has HOXD10 as a target whose reduction produces higher levels of 
RHOC, which stimulates cancer cell motility149. But miRNAs could be a good ally to 
distinguish different tumours and different subtypes of tumours as well as to predict 
their clinical behaviour. Some studies on the expression profile of miRNAs in bone 
marrow samples from patients revealed that it is possible to distinguish the different 
origins of tumours150. Moreover miRNAs could play an important role as specific 
miRNAs for identifying disease progression. In fact, researchers demonstrated that 
high miR-21 expression was associated with poor survival of patients with pancreas 
endocrine tumours or colon adenocarcinomas151,152. miRNAs could also be a 
therapeutic tool in tumours: a lot of attempts reconstituting in reduced gene expression, 
for example blocking a transcriptional repressor increasing a miRNA expression that 
target it, or reducing over-expressed genes through miRNAs are being made. miRNAs 
are one of the fundamental elements in the integrated regulation of gene expression 
since they are involved in the balance of gene regulating networks that determine the 
cells fate. Disruption of these pathways may contribute to cancer progression. 
Therapeutics as well as diagnostics and prognostics can take advantage of this new 
knowledge about miRNAs and their actions: clinical applications exploiting our 
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understandings of miRNA's functions will be the next great challenge in cancer 
research.  
 
5. Non-Hodgkin's  lymphomas 
The lymphoproliferative diseases are a group of illnesses due to neoplastic 
transformation of a lymphocytic clone. By examining the characteristics of these clones 
the researchers can determine the kind of disease: if the cells are circulating a 
lymphatic leukaemia affects the patients, whereas a lymphoma is present if the cells are 
found in lymphatic organs. The transformation causing this illness could be due to 
several different factors: exposure to toxic agents, genetic mutation, inheritance or 
chance. The lymphomas are a large group of diseases. The first discrimination is to 
distinguish between Hodgkin and Non-Hodgkin lymphomas. This division is based on 
the presence of a characteristic kind of cells: Reed-Sternbeng cells. If these cells are 
present, it is a Hodgkin lymphoma, if they are not it is a Non-Hodgkin lymphoma. The 
first group has a better characterization as a disease thanks to this classification. Non-
Hodgkin lymphomas are twice as common as Hodgkin lymphomas. Moreover, Non-
Hodgkin lymphomas contain a heterogeneous group of diseases, the majority of which, 
around 80%, originate from B lymphocytes153. The most common types are the 
follicular lymphomas and the diffuse large B-cell lymphomas, respectively at 22% and 
35%154. These diseases are often discovered at an advanced stage in different loci 
because no symptoms are recognisable during the initial period. For this reason it could 
be interesting to gain a better knowledge of these diseases so as to determine possible 
treatments.   
 
6. POK proteins 
POK proteins are a large family of proteins involved in the development, 
differentiation, and oncogenesis of living beings. A subgroup of these proteins is 
characterized by an N-terminal Poz domain and C-terminal Krüppel-type zinc finger 
domain. The POZ domain, also known as the BTB domain, mediates 
homodimerization and heterodimerization plus recruitment of corepressor/HDAC 
complexes155. This is a protein-protein interaction domain, originally identified in some 
zinc finger proteins of D.melanogaster and Pox virus. The POZ domain is a versatile 
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protein-protein interaction motif that participates in a wide range of cellular functions, 
including transcriptional regulation, cytoskeleton dynamics, ion channel assembly and 
gating, and targeting proteins for ubiquitination (Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Backbone superposition of the POZ domains of LRF, BCL6, and 
PLZF (Modified from David S. Waugh Elsevier Inc. 2006). 
 
 
The C-terminal Krüppel-type zinc finger domain mediates specific DNA recognition 
and binding. Many members of this large family, like B cell Lymphoma 6 (BCL6) and 
leukaemia/lymphoma related factor (LRF) have been characterized as important 
transcription factors, implicated in the development and oncogenesis.  
LRF is often aberrantly over-expressed in association with BCL6 in several kinds of 
tumours such as diffuse large B cell lymphoma (DLBCL) and follicular lymphoma 
(FL), the most common types of Non-Hodgkin lymphomas156. Moreover they have a 
common target: p53. In fact, as it will be explained in the following paragraphs, BCL6 
blocks this transcriptional factor in a direct way157 while LRF acts indirectly156. These 
evidences suggest a possible crosstalk between these factors in these kinds of tumours: 
they could be connected through a circuit to each other. 
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6.1 B cell Lymphoma 6 
B cell Lymphoma 6 (BCL6) is a protooncogene located on the chromosome 3 in the 
breakpoint affecting band 3q27158,159, the most frequent translocation in Non-Hodgkin’s 
lymphomas, characterized by a heterogeneous group of malignant diseases, the 
majority of which originates from B lymphocytes160,161. BCL6 is a 95 KDa protein and 
it is a transcriptional repressor162-164. It is able to directly bind the DNA through six C-
terminal zinc finger domains, each separated by a conserved stretch of seven amino 
acids (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
Figure 14. Functional domain of the BCL6 protein. Starting from N terminus 
there are: the Poz domain(1-130), the domain involved in the transcritional 
repression(191-386), the PEST domain (300-417), and at the C terminus (520-681) 
the zing finger domain. 
 
 Moreover BCL6 is able to cooperate with other proteins through the N-terminal POZ 
domain: this is an evolutionary conserved interaction domain required for homo- and 
hetero-dimerization of this family of proteins. Some of these molecules are the 
silencing mediator of retinoic acid and thyroid hormone receptor (SMRT), which in 
turn associates with both SIN3A and histone deacetylases (HDACs) to constitute a 
large repressing complex164,165. Other domains are present in the central part of BCL6 
as for example the PEST motif  that is critical for BCL6 protein stability. 
In fact, BCL6 protein is also phosphorylated by exogenous kinases in the PEST 
domain: this produces the fast degradation of the BCL6 protein through its 
ubiquitinization and proteasome's action166,167. Another mechanism that negatively 
controls BCL6 is acetylation by p300: it blocks the capability of this transcriptional 
 
transcriptional repression 
1    130              191               386            520         681 
300                 417 
 Poz domain                 PEST sequence             zinc-finger  motif 
          
NH2                                                                                                                                            COOH 
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repressor to interact with for example HDAC2168. Another important effect of  BCL6, 
in human B cell, is to thwart the response to DNA damage by inhibiting both a p53-
dependent and a MIZ-1 dependent pathway169. In fact by physically interacting with the 
transcriptional activator Miz-1, BCL6 suppresses the transcription of the cell-cycle 
arrest gene p21169. The BCL6 expression is present in different tissues, for example, in 
sub-groups of epidermal and neuronal cells170, but its main role is in the germinal 
centre: here BCL6 is constitutively expressed and its action is necessary for the 
development of germinal centre and the suppression of p53 action157,171,172. In fact, 
BCL6 binds to the p53 promoter by silencing the transcription and by cooperating with 
MIZ-1 it blocks p21 cyclin dependent kinase, that produces cell cycle arrest. Germinal 
centres are dynamic structures within secondary lymphoid tissues that are responsible 
for the generation of B cell memory and high-affinity antibodies. These processes, in 
which BCL6 level increases, are necessary for B cells after the activation of T-cell 
dependent antigens and they allow the class switch recombination and the somatic 
hypermutation which physiologically occur in germinal centre cells of lymphatic 
organs173,174. In this way B cells can produce antibodies with high affinity for the 
antigen. BCL6 is also an essential requirement for GC formation, because mice lacking 
BCL6 cannot form these structures. Moreover in B-cell lines BCL6 prevents apoptosis 
induced from DNA damage.  
When cells differentiate the down-regulation of BCL6 occurs. This gene is involved in 
chromosomal translocations in 40% of diffuse large B cell lymphoma and 
approximately 5–10% of follicular lymphoma cases175-178. Under these conditions the 
mutation is not present in the coding region but in the promoter or in the 5' part. So 
BCL6 can not be regulated at the end of the cell differentiation.  
 
6.2 Leukaemia/lymphoma related factor 
Leukemia/lymphoma related factor (LRF)179, that is encoded by the Zbtb7a gene, is 
also known as pok erythroid myeloid ontogenic factor (Pokemon)156, factor binding to 
IST-1 (FBI-1)180-183 or osteoclast derived zinc finger (OCZF)184. LRF is a 
transcriptional repressor of 67 KDa involved in many cellular processes such as viral 
infection180,181,185, differentiation179, inflammation186 and oncogenesis156.  LRF is a 
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member of the POK family of transcriptional repressors and it is over-expressed in 
some kinds of tumours (Fig. 15).  
 
 
 
 
 
 
 
Figure 15. Functional domain of the LRF protein. At the N terminus there is the 
Poz domain and at the C terminus the zinc-finger domain. 
 
 
In mouse embryonic fibroblast it is necessary for the transformation induced by two 
oncogenes. When LRF is deleted, these cells are resistant to oncogene-mediated 
cellular transformation. Instead the cells transformation is produced when LRF is co-
expressed with another oncogene187. LRF is a transcriptional repressor of ARF that in 
turn is able to activate p53 in an indirect manner. In this way cells can be induced 
toward senescence or apoptosis, if at the same time there is an oncogene over-
expression. Moreover LRF inactivation in mice produces the death of embryos due to a 
severe anaemia and an impaired cellular differentiation in many tissues. Microarray 
analysis shows that LRF is over-expressed in many different kinds of tumours: breast, 
lung, colon, prostate and bladder carcinomas. LRF is also one of the main regulatory 
genes in determining the development of common lymphoid progenitor cells in B or T 
cells: in the bone marrow, where LRF is not expressed, the cells are committed towards 
B development while in the thymus LRF is expressed and is able to repress the Notch 
pathway188. The Notch is a family of transmembrane proteins with an extracellular 
domain that induce proteolytic cleavage and release an intracellular signal. These 
proteins are involved in many different processes including T cell lineage commitment 
from common lymphoid precursor188. LRF plays an important role as a protooncogene 
also in Non- Hodgkin lymphomas: it is over-expressed in 80% of FL and in 60% of 
DLBCL156. LRF is involved in many other different processes. In fact it is necessary 
for the differentiation from preosteoclasts to osteoclasts184 and from preadypocytes to 
NH2                                                                                                                                         COOH 
Poz domain                            zinc-finger domain 
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adypocytes189. It seems to produce the exit from the cell cycle through the repression of 
genes such as Cyclin A189. Moreover it represses the cartilaginous markers in non-
condrocytic cells190. During the mouse embryogenesis until the 11.5th day LRF is 
expressed just in haematopoietic tissue and afterwards it extends its expression to limb 
buds, pharyngeal arches, tail bud and neuronal tube179. In inflammation processes LRF 
is able to interact with Nuclear Factor-kappaB (NF-kappaB) transcriptional factor. In 
this way NF-kappaB moves from the cytoplasm to the nucleus where it acts as a 
transcriptional factor in response to inflammatory stimuli186.   
 
7. The circuit 
 
We followed the hypothesis that the over-expression of the two protooncogenes BCL6 
and LRF are causally correlated in Non- Hodgkin's lymphomas as suggested in 
Pandolfi's paper156. To verify this idea we tested these two genes in the Dohh2 cell line: 
a cell line derived from a human B cell lymphoma which over-expresses both LRF and 
BCL6. Using our data and data taken from the literature demonstrated in different 
model systems, we reconstructed a hypothetical network that includes both these genes 
( Fig. 16). We briefly described the members of this circuit and the data that are present 
in literature: 
1. p53, which is under BCL6 direct  negative control157 and LRF indirect negative 
control156 via p14-ARF down-regulation;  
2. miR-34a, which is under p53 positive control191; 
3. miR-145, which is an important link between p53 and c-Myc192, is under p53 
positive control; 
4. c-Myc,  which negatively controls miR-30 family transcription73; 
5. miR-20a, which is involved in a complex feed back loop with c-Myc and 
E2F173;  
6. E2F1, which induces p14-ARF transcription252 thus promoting p53 up-
regulation;  
7. LRF, which is negatively controlled by miR-20a193; 
8. miR-28251 and p14187, which are negatively controlled by LRF.  
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Figure 16. Hypothetical circuit connecting BCL6 and LRF. 
 
7.1 p53 
p53 is negatively regulated by BCL6 in a transcriptional manner as demonstrated by 
Dalla Favera157. The p53 gene is one of the most important tumour suppressor genes in 
human cancer transcribed from gene TP53: its molecular mass is 53 KDa. It encodes a 
gene regulatory protein that is activated by damage to DNA: in this manner it is 
involved in the cell-cycle control, in apoptosis, and in the maintenance of genetic 
stability194,195. These functions are fundamental in protecting the organism against 
cellular damage and disorder: p53 is mutated in about half of all human cancers196. The 
p53 protein has a dual role, regulating both progression through the cell cycle and, if 
the damage is extensive, it promotes senescence, or the initiation of apoptosis. Normal 
cells stop dividing after a finite number of cell divisions because they lacks of 
endogenous telomerase: the enzyme that elongates telomere sequences in DNA. This 
provokes telomere shortening and beyond a certain limit it triggers a the activation of 
the ATM/ATR–p53 pathway inducing the replicative senescence197,198. Under normal 
conditions very little p53 protein is found in most of the body's cells: it is not required 
for development. p53 interacts with another protein, Mdm2, that acts as a ubiquitin 
ligase: it targets p53 for destruction by proteasomes. On the contrary, after exposure to 
radiation or certain chemicals, when chromosomes are damaged, phosphorylation of 
BCL6 p53 
miR-34  
 
miR-145 
c-Myc 
miR-30 
miR-20 
E2F1 
LRF p14 
miR-28 
MDM2 
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p53 occurs: this decreases its degradation because it blocks its binding to Mdm2199,200. 
As a consequence p53 increases and promotes the transcription of its target genes. For 
example p53, binding specific sequences on the DNA, induces the transcription of p21: 
a regulatory gene whose protein product binds to Cdk complexes required for entry into 
and progress through S-phase201. By blocking the kinase activity of these Cdk 
complexes, the p21 protein prevents the cell from entering the S phase, replicating its 
DNA and arresting them in G1 phase202. p53 is also involved in the activation of 
apoptosis because it promotes the transcription of genes of BCL2 family: these proteins 
promote the release of cytochrome c from mitochondria203. Cells defective in p53 fail 
to show these responses. In fact, the loss of p53 activity can be dangerous: it may allow 
faulty mutant cells to continue through the cell cycle, it may allow them to escape 
apoptosis and it may lead to the genetic instability characteristic of cancer cells, 
allowing further cancer-promoting mutations to accumulate as the cells divide. For 
example the rare genetic disease known as ataxia telangiectasia is caused by a defect in 
one of the protein kinases that phosphorylates and activates p53 in response to X-ray-
induced DNA damage. Patients affected by this disease are very sensitive to X-rays due 
to the loss of the DNA damage checkpoints, and they consequently suffer from X-rays-
induced cancer in an higher percentage. Another way through which p53 operates is the 
miRNAs transcription. In fact, p53 could modulate the cell fate not only as previously 
described but also through miRNAs, involving them in a complex network. Some 
miRNAs under p53 control are miR-15 and miR-1661, targeting the anti-apoptotic 
BCL2 protein, let-7, that down-regulates Ras and miR-221147, which, in turn, down-
regulate the CDK inhibitor p27. Researchers have demonstrated that miR-34a191 and 
miR-145192 transcription is also regulated by p53 action.   
 
7.2 miR-34a 
The miR-34 family is composed by three members: miR-34a, miR-34b and miR-34c 
that are directly regulated by p53191. miR-34a resides on chromosome 1p36 and both 
miR-34b and miR-34c are generated by processing of a bicistronic transcript derived 
from chromosome 11q23 (termed miR-34b/c). These miRNAs are described as tumour 
suppressors: they are down-regulated in some tumour specimens as miR-34b/c was 
reported in a subset of lung cancer patients191, while miR-34a expression frequently 
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occurs in pancreatic cancer cells, and was detected in 36% of clinical colon cancer 
specimens204. c-Myc is one of the targets of miR-34a73. It has been demonstrated that 
enforced expression of miR-34a promotes apoptosis and up-regulation of miR-34b/c 
reduces proliferation and adhesion-independent growth of lung cancer cells191. Besides, 
in animal studies, the introduction of miR-34a also suppresses the cell proliferation of 
human colon cancer cells204.  
 
7.3 miR-145 
miR-145 is located on chromosome 5 (5q32-33) within a 4.09 Kb region. This is a 
well-known fragile site in the human genome: it is deleted in 11% of sporadic breast 
cancers205. Human miR-145 is enriched in germ line and mesoderm-derived tissues, 
such as uterus, ovary, testis, prostate, spleen, and heart206. Although the primicroRNA 
structure has not been identified, it is suggested to be co-transcribed with miR-143 
because both are localized close to each other in the chromosome207. The 
transcriptional induction of miR-145 by p53 takes place in response to stress such as 
serum starvation192. miR-145 is described as a tumour suppressor. In fact, it is under-
expressed in both breast and colon cancer specimens, compared to matched normal 
tissue samples192. It is worth mentioning that, this down-regulation of miR-145 seems 
to depend on the type of tissue: its down-regulation is described as more prominent in 
colon cancer than in breast cancer. Researchers demonstrated that miR-145 has a 
profound inhibitory effect on two colon cancer cell lines in vitro model by suppressing 
insulin receptor substrate-1 through binding to its 3’-UTR208. Consistent with this 
finding, miR-145 can also significantly reduce cell growth in B-cell lymphoma cell 
lines. This miR-145-mediated inhibition of cell proliferation is likely due to direct 
targeting c-Myc oncogene by directly binding to its 3’-UTR and down-regulating it. It 
has been described that miR-145 is inversely correlated to levels of c-Myc in breast 
cancer  and in B lymphoma cell lines 192. 
 
7.4 c-Myc 
c-Myc is a basic helix-loop-helix transcription factor which directly regulates the 
transcription of a diverse array of target genes. Through this target gene network, c-
Myc globally reprograms cells to drive proliferation and, in some settings, induce cell 
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death209. c-Myc can be activated by the small GTPase Ras, which leads to the 
activation of a MAP kinase cascade that, by uncertain mechanisms, leads to increased 
levels of the gene regulatory protein Myc210. Myc promotes cell-cycle entry: it 
increases the transcription of genes that encode D cyclins, thereby increasing G1-Cdk 
(cyclin DCdk4) activity211. In addition, Myc increases the transcription of a gene that 
encodes a component of the SCF ubiquitin ligase. This mechanism promotes the 
degradation of the CKI protein p27, leading to increased cyclin E-Cdk2 activity212. c-
Myc can also play a role in tumour formation: Myc is frequently amplified in cancers, 
it can also be made active by a chromosomal translocation, amplification or virus 
infection. For example, as a consequence of a rearrangement, in Burkitt's lymphoma a 
translocation brings the c-Myc gene under the control of sequences that normally drive 
the expression of antibodies in B cells. As a result, the mutant B cells proliferate to 
excess and form tumours. Similar specific chromosome translocations are common in 
lymphomas and leukemias213. 
High levels of c-Myc cause the activation of p14ARF, which binds and inhibits Mdm2 
and thereby causes increased p53 levels: this could cause cell-cycle arrest or apoptosis. 
c-Myc may also promote E2F activity directly by stimulating the transcription of the 
E2F gene214-216. It has been demonstrated that c-Myc is able to regulate both positively 
and negatively the miRNAs transcription. c-Myc represses miR-30 family and it 
induces the expression of microRNAs within the miR-17–92 cluster: through 
chromatin immunoprecipitation researchers confirmed that c-Myc binds to its 
recognition sites, E-boxes, upstream of this cluster217. This regulation is a part of a 
complex feed back loop network that involves  c-Myc and E2F1, that have been shown 
to activate each other’s transcription, and the miRNAs belonging to the cluster of miR-
1773. Some of these miRNAs, such as miR-20a, are also able to target E2F1 mRNA. 
Moreover, the E2F transcription factors can also induce the microRNAs in the miR-17–
92 cluster: the over-expression of E2F1 or E2F3 results in increased miR-17–92 
promoter activity. This complex network can be explained by the c-Myc and E2F1 
roles: miR-17–92 may act as a brake on this possible positive feedback loop, thus 
helping to ensure a tightly controlled expression of c-Myc and E2F1 proteins. 
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7.5 E2F1 
E2F are a family of proteins binding to specific DNA sequences in the promoters of 
many genes that encode proteins required for the S-phase entry, including G1/S-cyclins 
and S-cyclins. Members of the E2F family are downstream effectors of the 
retinoblastoma protein (Rb) tumour suppressor: an inhibitor of cell-cycle 
progression218. When cells are stimulated to divide by extracellular signals, active G1-
Cdk accumulates and phosphorylates Rb, reducing its affinity for E2F. The Rb then 
dissociates, allowing E2F to activate S-phase gene expression. Rb plays a fundamental 
role in controlling cell cycle progression. Transcriptional activation of S phase-
associated genes is only one facet of E2F activity: it is known that E2Fs both 
transactivate and repress gene expression to regulate a wide range of biological 
processes, including DNA replication, mitosis, the function of DNA damage 
checkpoints, DNA repair, differentiation, autophagy and apoptosis219-221. E2F 
transcription factors can increase the transcription of its own gene: E2F-dependent 
transcription of G1/S-cyclin and S-cyclin genes leads to increased G1/S-Cdk and S-
Cdk activities, which, in turn, increase Rb phosphorylation and promote further E2F 
release. Moreover, the increase in G1/S-Cdk and S-Cdk activities enhances the 
phosphorylation of Hct1 and p27, leading to their inactivation or destruction. In 
mammals, the E2F family comprises eight genes (E2F1–8), which give rise to nine 
distinct proteins221. E2F family members have been categorized into subfamilies on the 
basis of their transcriptional activity, structure and interaction with Rb family members. 
E2F1, E2F2 and E2F3A, which interact only with Rb, constitute one subfamily and are 
often referred to as the ‘activator E2Fs’, as they are believed to work mainly in 
activating gene expression. E2F4–8 largely operate in the repression of gene expression 
and are generally referred to as the ‘repressor E2Fs’. E2F1 is particularly interesting: it 
could induce apoptosis by both p53-dependent and p53-independent pathways220. It is 
generally believed that up to a certain threshold, E2F1 expression drives cellular 
proliferation, but an excessive expression of this protein appears sufficient to induce 
cell death. E2F1 activates p53222, p53 and E2F1 co-regulate pro-apoptotic genes (for 
example the BH3-only protein-encoding genes PUMA and NOXA)223,224 and p53 and 
E2F1 negatively regulate anti-apoptotic genes such as BCL2 and MCL1225,226. 
Moreover data suggest that Smac/DIABLO may act as a target gene for E2F1 and 
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contribute to a novel E2F1-induced apoptosis via p53-independent pathway227. E2F1 
and p53 cooperate in restricting tumorigenesis by inducing cell death: E2F1 carry out 
both oncogenic and tumour suppressive activities. E2F1 controls also p14 
transcription252. p53 and E2F1 are stabilized in response to various stresses, in 
particular DNA damage, and both are phosphorylated by ataxia telangiectasia mutated 
(ATM), as well as the checkpoint kinases cHK1 and cHK2, and this phosphorylation 
contributes to their stabilization228,229. Additionally, phosphorylation by these kinases 
activates p53 and fine-tunes its response to DNA damage. Similarly, DNA damage-
induced phosphorylation modulates E2F1 activity. Specifically, cHK1 and cHK2 were 
shown to promote E2F1 stabilization and activity after genotoxic stress and thereby 
contribute to E2F1-induced up-regulation of p73 (a member of the p53 family) and 
consequently apoptosis230. Acetylation of p53 by p300 and PcAF in response to DNA 
damage is associated with DNA binding and transactivation by p53231-233. Likewise, 
E2F1 is acetylated by p300 and PcAF29–31 and this stabilizes E2F1. E2F1 is also 
described as influenced by miRNAs control: the expression of E2F1 was negatively 
regulated by miR- 17-5p and miR-20a in HeLa cells73. It is involved in a complex feed 
back loop with c-Myc and the cluster of miR-17.5p. c-Myc protein simultaneously 
activates E2F1 transcription and limits its translation, allowing a tightly controlled 
proliferative signal. There is a model in which miR-17-92 promoted cell proliferation 
by shifting the E2F transcriptional balance away from the pro-apoptotic E2F1 and 
toward the proliferative E2F3 transcriptional network234. 
 
7.6 miR-20a 
The miR-20a is located in the miR-17–92 cluster, which contains seven mature 
microRNAs (miR-17–5p, miR-17–3p, miR-18a, miR-19a, miR-20a, miR-19b, and 
miR-92–1)67,137. These microRNAs are organized in a polycistron: they are all 
transcribed as a single pri-microRNA, and then subsequently processed to form the 
individual microRNAs. The entire miR-17–92 cluster is located within the third intron  
located at 13q31–q32. The close proximity of the six clustered microRNAs to each 
other (all of them encompass only 800 base pairs of genomic DNA) makes it possible 
for all of the microRNAs to be transcribed and expressed similarly73,235. In fact, a recent 
analysis of the expression microRNAs in hematopoietic cell lines revealed similar 
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expression patterns for all the microRNAs in this cluster in the samples analyzed236. 
This cluster is positively transcriptionally regulated by c-Myc. miR-20a is described 
both as a tumour suppressor and as an oncogene68,134. It is involved in a complex 
network that links c-Myc, E2F1 and miR-20a itself73. miR-17–5p, in particular, is 
expressed at low levels in multiple breast tumour cell lines and has antiproliferative 
effects on breast cancer cells237. The locus in which the miR-20a is located is frequently 
amplified and this miRNA is up-regulated in human B cell lymphomas and in lung 
cancer, but it also plays an oncogenic role: the repression of miR-20a activity markedly 
increases the death of PC3 prostate cancer cells, whereas over-expression of miR-20a 
significantly increases colony formation of these cells when subject to treatment with 
doxorubicin, an apoptosis-inducing, chemotherapeutic agent134,238,239. It has also been 
demonstrated that miR-20a is able to target and repress LRF in MEF, which causes 
cellular senescence193.  
 
7.7 p14  
The locus INK4A-ARF is transcribed for two different proteins through alternative 
splicing: p16INK4a , that controls the retinoblastoma protein, and a second protein called 
p19ARF in mice and p14ARF in men240. The second one is important for the half-life of 
p53: p14 is able to bind directly MDM2 protein and block it. MDM2 controls p53 
activity in two manners: it affects p53's stability by acting as an E3 ubiquitin ligase that 
causes p53 to be targeted by the degradation apparatus and acts directly at the N-
terminus to inhibit the transactivation activity of p53. p14 is described as 
transcriptionally controlled by LRF187 and E2F1 252.  
 
8. Aim of the project  
The aim of this project consists in studying the possible correlation between BCL6 and 
LRF in cell lines derived from  Non- Hodgkin's lymphomas. Since a negative feed back 
loop should link BCL6 and LRF (following the interaction showed in the circuit), the 
double increase of these genes found in Non- Hodgkin's lymphomas could be involved 
in the high proliferation rate typical of tumor cells.  
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Materials & methods 
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1. Cell culture  
The human follicular B cell lymphoma lines Dohh2 (follicular lymphoma), SU-DHL4, 
Karpas (diffuse large cell lymphomas) and Ramos and Raji (Burkitt’s type lymphomas) 
were seeded at 6 x105 cells/ ml and they were grown in RPMI 1640 medium containing 
10% FBS supplemented with glutamine and antibiotics. 
The human follicular B cell lymphoma lines were obtained from Ospedali Riuniti of 
Bergamo. 
HEK 293T and HeLa cells were grown in low glucose DMEM+10% FBS + antibiotics. 
These cells were plated at 6x105 cells/100 cm2. These cell lines were from our 
laboratory. 
All cells were grown at 37°C in a humidified atmosphere containing 6% CO2 . 
Naïve B cell CD19+ CD27- were purified from human tonsils and blood with Miltenyi 
Biotec kit.   
 
 
2. Western blot 
Proteins (about 30 μg/ lane) were separated on 8% SDS-polyacrylamide gel and 
transferred to nitrocellulose membrane. Immunoblotting of the membranes was 
performed using the following primary and secondary antibodies as reported in the 
Table n.3. Signals were revealed after incubation with recommended secondary 
antibody coupled to peroxidase by using enhanced chemiluminescence. Scanned 
images were quantified using Scion Image software. Anti-BCL6 (sc-858), anti-c-Myc 
(sc-40), anti-E2F1 (sc-193), anti-LRF (sc-13E9) anti-actin (sc-47778) were from Santa 
Cruz, anti-p53 (sc-DO7) was from DAKO, anti-tubulin (sc-2168) was from Sigma. 
Secondary antibody were anti-rabbit (sc-D2910), anti-mouse (sc-L1409), anti-
Armenian Hamster (sc-E2709) from Santa Cruz. 
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Table n.3 Concentration of antibodies for immunoblotting  
Gene I Antibody II Antibody 
LRF 1:200 1:500 
BCL6 1:2000 1:1000 
p53 1:1000 1:1000 
c-Myc 1:200 1:200 
E2F1 1:200 1:200 
Tubulin 1:1000 1:2000 
b-Actin 1:3000 1:3000 
 
 
3. RT-PCR 
RNA was extracted using miRNeasy (QIAGEN) or Trizol Reagent (Invitrogen). After 
DNase treatment, we used 1 μgr of RNA to synthesize cDNA by miScript system 
(QIAGEN) or using SuperScript II reverse transcriptase with random primers. 
Real time PCR were performed with Light Cycler 480 Roche using Taqman probes or 
with SyberGreen (Roche). GAPDH gene and β-actin were used as internal standard. 
Mature miRNAs were quantified using the miScript System according to the 
manufacturer's instruction. U6 gene was used as internal standard. 
All PCR reactions were run in triplicate and miRNAs and genes expression, were 
calculated using Pfaffl's method 241. 
 
 
4. Etoposide treatment  
For explorative experiments cells were seeded 9 hours before the treatment. The drug 
was added for 2,4,6, or 16 hours at the concentration of 10 μM and then the cells were 
collected for western blot, RT-PCR  and cell cycle analyses.  
When we tested Dohh2 cells these were seeded at a density of 2 x 105 cells / ml 36 
hours before the etoposide treatment. 10 μM etoposide (Sigma) was added to the 
medium for 6 hours and after this the cells were harvested. As control we used 
untreated cells seeded and harvested in the same way as treated cells.  
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5. Cell cycle profile analysis 
 
Dohh2 cells were seeded at the concentration of 5x105 for 24 hours. Then they were 
treated with 5μM etoposide for 16 hours. Cells were fixed with 95% ethanol  and 
stained with propidium iodide ( 50μg/ml)   for 30 minutes with RNase A. Both these 
products were from Sigma. 
As control we used  untreated Dohh2 cells  seeded and stained in the same way. DNA  
profiles, performed at FACS flow cytometer (Becton-Dickinson), were performed 
using 1x104 cells. 
 
6. Proliferation assay 
For miR-145 transfection, and etoposide treatment (6 hours) treated cells were seeded 
in 12-well plates in triplicates. After 105 cells were seeded in a 12 well in a volume of 2 
ml of complete medium and were counted every 24 hours for 96 hours. At  48 hours 
from the transfection we added 1 ml of complete medium at each well. The same 
protocol was applied for the evaluation of proliferation of silenced population.  
 
7.MTT assay 
MTT  assay is a colorimetric method for determining the number of proliferating cells. 
This MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is 
from Promega. Dohh2 cells were treated or not with different doses of etoposide for 16 
hours. We seeded them at the concentration of  104  cells a  in 96 well plates in 100 μl 
and incubated at 37°C in a humidified atmosphere containing 6% CO2. 48 hours after 
etoposide treatment we added at each point 20μl  of reagent and we incubated the cells 
in a humidified incubator for one hour. The quantity of product as measured by the 
absorbance at 490nm is directly proportional to the number of living cells in culture. 
 
8. Methyl cellulose assay 
 
The methyl cellulose dust was dissolved at the final concentration of 2% (wt/vol) in 
RPMI 1640 culture medium. For methyl cellulose assay 3-cm plates were covered in a 
methyl cellulose base layer (2%). A top layer containing 105 cells to be assayed was 
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suspended in 500 μl of RPMI 1640 medium containing 10% FBS, glutammine and 
antibiotics that was mixed at 500 μl of methyl cellulose (2%). This mixture was 
pipetted on top of the base layer. Plates were grown at 37° C in a humidified 
atmosphere containing 6% CO2 in humidified boxes. After 5 days, colonies were 
counted. 
 
9. Transfection with miR-145 
Si-miR-145 and negative control (miR-NC) miRNAs were purchased from Gene 
Pharma Shanghai, China. The oligonucleotides used were reported in the figure 17.  
Proliferating cells were harvested, washed in PBS and resuspended in the transfection 
solution. Then they were transiently transfected into Dohh2 cells at the concentration of 
500 nM each using Amaxa elettroporator (LONZA) according to the manufacturer’s 
instructions. Cells were harvested and analysed 24 hours post nucleofection. 
 
has si-miR-145 
 
 
has si-miR-NC 
 
 
Figure 17. si-miR-145 and si-miR-NC sequences. Some mutations were inserted 
at 5' and 3'ends to determine the choosing of the mature miRNA into the cells 
thanks to increased its thermodynamic stability.  
 
 
10. Stably silenced Dohh2 
Population of Dohh2 cells + BCL6i or the empty vector were established in our 
laboratory. In the pSUPER.retro plasmid (Fig.18) was inserted a si-RNA specific for 
BCL6 (Fig. 18).  The pSUPER.retro plasmid is from OligoEngine. 
The sequence of the siRNA was cloned between the unique BglII and HindIII enzyme 
sites. The siRNA sequence is followed by a 9 nt spacer sequences and, after this, by the 
antisense sequences complementary to the siRNA of interest. This sequence was 
5’-GUCCAGUUUUCCCAGGAAUCCCUAA-3’ 
    AGGGAUUCCUGGGAAAACUGUUCAA 
5’-UUCUCCGAACGUGUCACGUTT-3’ 
    ACGUGACACGUUCGGAGAATT 
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annealed with a complementary one dissolving  the oligos in sterile, nuclease-free H2O 
and incubating the mixture at 70°C.  The resulting transcript of the recombinant vector 
forms a 19–base pair stem-loop structure: a functional siRNA. We transiently transfect 
pSUPER.retro vector directly into mammalian cells through electroporation: 5 x 106 
cells were electroporated with 15 μgr of plasmid and we obtained a stably insertion of 
the plasmid in these cells. The pSUPER.retro plasmid expresses the gene encoding the 
resistance at puromycin. 24 hours after transfection 5μgr / ml of puromycin was added 
at the culture medium. These cells were plated 6x105 /ml every three days with 5μgr / 
ml of puromycin.  
 
 
d) 
hsa-siRNA-BCL6i 
5’-GUCGAGACAUCUUGACUGAUU-3' 
 
Figure 18. pSUPER.retro and siRNA-BCL6 sequences. Schematic representation 
of p-SUPER vector: a) an hypothetical si-RNA sequence appropriately designed to 
form an hairpin structure(b). The si-RNA sequence inserted between the restriction 
sites of enzymes BglII and HindIII(c). d) BCL6i siRNA sequence. 
 
 
11.Predictive algorithm 
TargetScan is the predictive algorithm that allowed to us to identify several miRNA 
families potentially targeting LRF and BCL6. It is  available online  at the site http:// 
www.targetscan.org/ 
 
51 
 
12. Expression vectors 
3'UTR of LRF and BCL6 was amplified through PCR from genomic DNA derived 
from HeLa cells. PCR reactions were performed using the high fidelity Herculase Taq 
enzyme (Stratagene), and specific primers ( from Invitrogen) reported in the figure 19. 
 
 
a)BCL6 (sense) 
5’TAAGGAGTGTTGATGCTTTCGTC3’             
BCL6 (antisense) 
5’GAGCTGAGTGGGAGGTCCTT3’ 
 
 
b) 
LRF  (sense) 
5’CATAAGCTTAAGAGAAGCACTTTAAGGACGAG3’              
LRF  (antisense) 
5’GCATCTAGAGATAGGAAGGCAAAGAGCA3’ 
 
Figure 19. The primers used for 3'UTR PCR amplification of BCL6 (a) and 
LRF (b). 
 
At first we cloned the PCR products in the p-GEM-T-Easy because in its multiple 
cloning site of pGEM-T-Easy contains the coding region of the enzyme of  β-
galactosidase (Fig.20). 
 
 
 
 
 
 
 
 
Figure 20. Schematic representation of pGEM-T-Easy plasmid. 
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Whether the insert is cloned in the plasmid this enzyme is inactive. The recombinant 
clones could be directly identified by colour screening plating the bacteria in agar 
containing X-gal, a chromogenic substrate. The colonies screening were made through 
their colour white or blue. In fact the white colonies had the plasmid in which the 
3'UTR was inserted. After the plasmid was extract from bacteria and the 3'UTR was 
excised from pGEM-t-easy. 
In the LRF PCR product into the primers sequences were inserted the recognition sites 
for the restriction enzymes. These restriction sites were used to insert the fragment in 
the pGEM-T-easy plasmid. We used the XhoI and after HindIII enzymes to extract the 
LRF 3'UTR from the pGEM-T-easy plasmid. All the enzymes used were from New 
England Biolabs.  
The PCR product of BCL6 3'UTR was inserted in the pGEM-T-easy using the 3' 
terminal thymidine present at to both ends of this construct. Then the 3'UTR was 
excised from the pGEM-T-easy using the enzymes BamHI and EcoRI.  
Fluorescence constructs were made by ligating these fragments containing the wild-
type 3' UTR in the sites of the Multi Cloning Site of pE-GFP vector (Fig.21) . A stop 
codon was present between the coding sequence of the reporter gene and the 3’UTR 
sequence. In this way, the possible unfolding or toxicity associated with a chimeric 
GFP protein could be avoided. 
 
 
 
 
 
 
 
 
 
Figure 21. Schematic representation of pE-GFP-C1 plasmid. 
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By site directed mutagenesis mutant versions of the 3’UTR were also prepared using 
Sigma’s QuikChange Multi Site-Directed Mutagenesis Kit. The mutated basis were 
reported in Suppementary (Fig. 63- 64).   
 
13. E-GFP reporter assay 
HEK 293T cells (a recipient cells) were transiently transfected using Polifect 
(QIAGEN) using the manufacturer’s protocol for 24 well plates: HEK 293T cells were 
seeded at a density of 3x105 cells x 24 well dish. 24 hours later, 150 ng of pE-GFP-C1  
with the Zbtb7a 3'UTR were cotransfected with 75–300 ng of si-miRNAs under test. 
Si-miR-302 and miR-30 were purchased from Gene Pharma Shanghai, China (Fig. 22). 
Cells were harvested and analysed 24 hours post transfection, fluorescence was 
quantified by cytofluorimetry (FACSCalibur, Becton Dickinson). At each point we 
analysed 1x104 cells from three independent experiments.  The rules governing the 
pairing between miRNA and its target mRNA establish that maximal complementarity 
is usually restricted, but it is fundamental to the seed: nucleotides 2 to 8 in the 5’ end of 
the miRNA. In the mutant 3’UTR we changed three bases inside the seed match 
corresponding to the seed of the miRNA under testing, so we  used the reporter 
mutated plasmid to normalize the fluorescence values. 
 
a) 
hsa-si-miR-30 
5’-UGUAAACAUCCUACACUCUCAGCUU-3' 
    GCUGAGAGUGUAGGAUGUUUUAAUU 
 
b) 
hsa-si-miR-302 
5’-UAAGUGCUUCCAUGUUUUAGUAGUU-3' 
     CUACUAAAACAUGGAAGCACAAAUU 
 Figure 22. si-miR-30 and si-miR-302 sequences. 
 
14. Statistical analyses   
The data were analysed through Student’s t test to verify the differences between the 
samples under test and the control. 
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Results 
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Lymphomas are a broad and complex group of cancers that are usually classified as 
Hodgkin and Non-Hodgkin's lymphomas. The Non-Hodgkin's lymphomas are divided 
in turn into sub-groups: Burkitt and non-Burkitt lymphomas. BCL6 and LRF are two 
transcriptional repressors, members of the POK protein family, which behave as 
oncogenes in these tumours. Since a positive correlation between the expression level 
of BCL6 and LRF in Non-Hodgkin's lymphoma samples has been found187, we focused 
on them. In particular, we studied a sub-set of cell lines derived from non-Burkitt’s 
lymphomas, (namely Dohh2 a Follicular Lymphoma (FL), SU-DHL4 and Karpas two 
Diffuse Large B Cell Lymphoma (DLBCL) and Burkitt lymphomas (namely Ramos 
and Raji). Even if the BCL6-LRF correlation was found only in FL and DLBCL we 
included in our preliminary analyses also Raji and Ramos. In particular in Ramos had 
been demonstrated that BCL6 is able to control p53157.  
 
 1. BCL6 and LRF expression in Non-Hodgkin’s lymphoma cell 
lines. 
 
We performed a preliminary screening to identify which cell lines over express both 
BCL6 and LRF. 
 
1.1 BCL6.  
We quantified BCL6 protein through western blot, using HeLa cells as negative 
control172 and Ramos as positive control 157. BCL6 was more highly expressed in all 
lymphoma cell lines under test (Fig. 23).  
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Figure 23. Western blot and quantification of BCL6 in Non-Hodgkin’s lymphoma 
cell lines.  The protein level was normalized to the tubulin protein level of each sample 
as an internal control. Then the average values for the corresponding cell lines under 
test were normalized to the expression level of control cells. 
All tested cell lines showed a significant BCL6 expression: ranging from 4 to 15 times 
the HeLa control Raji  P<0.0001 , Karpas P=0,0011 , Dohh2 P=0,0024 , Ramos 
P=0,0016 , SU-DHL4 P=0.0065. 
 
 
 
1.2 LRF.  
We then quantified LRF protein by western blot analysis, using Ramos cells as 
negative and HeLa as positive control251. LRF was more highly expressed in Raji, 
Karpas and Dohh2  (Fig. 24).  
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Figure 24. Western blot and quantification of LRF in Non-Hodgkin’s lymphoma 
cell lines. The protein levels were calculated as reported in the Fig. 23. LRF was 
significantly increased in Raji P<0.0001 , Karpas  P=0,0205 , Dohh2 P=0,0079. 
 
 
These results suggested that both the Follicular Lymphoma cell line, Dohh2, and the 
Diffuse Large B cell lymphoma cell lines, Karpas and SU-DHL4, could be suitable for 
our investigation.  
 
 
1.3. The pathway BCL6-LRF. 
As described in the aim, some other transcription factors (i.e. p53, c-Myc and E2F1) 
and miRNAs (i.e. miR-34a, miR-145 and miR-20a) could have an important role in the 
hypothetical circuit BCL6-LRF we proposed (Fig. 16). We also quantified the 
expression level of three members of miR-30 family: miR-30a, miR-30c and miR-30e 
since these group of miRNAs are under c-Myc transcriptional control73, as well as the 
level of miR-28 under LRF control (Fig. 25). We used Naïve B cell CD19+ CD27- as 
control because these are non activated B cells where the BCL6 and LRF proto-
oncogenes are not expressed. 
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Figure 25. miRNAs expression profile in Non-Hodgkin’s lymphoma cell lines. 
miRNAs expression levels were measured through q-RT-PCR (using the U6 RNA as 
internal standard) and it was normalized to corresponding Naïve value. 
 
The level of some miRNAs appear to characterize these Non-Hodgkins B cell 
lymphomas from Naïve B cells: in particular, miR-20a is always over-expressed while 
miR-28 is under-expressed. We observed that miR-34a was slightly up-regulated in the 
tested cell lines, with the exception of Ramos cells. miR-145 was slightly under-
expressed in Dohh2 and Karpas, while it was strongly up-regulated in SU-DHL4. miR-
30 family expression varies according to the member of the family for example while 
miR-30a is over-expressed in all lymphoma cell lines, the other members of the family 
do not change significantly in comparison to Naive B CD19+ CD27- cells.  
At this point of the molecular analysis we decided to focus on two cell lines Dohh2 and 
SU-DHL4, which over express both BCL6 and LRF, and are representative 
respectively of Follicular Lymphomas and Diffuse Large B cell lymphomas. 
 
 
1.4 Etoposide treatment as an approach to test the  BCL6-LRF pathway 
via TFs and miRNAs.  
Etoposide is a chemotherapeutic drug derived from the mandrake plant, often used in 
combination with other antitumoral drugs242. It is known that BCL6157 can be down-
regulated by this drug. Hence, we decided to modulate BCL6 levels using this 
chemotherapeutic agent. Etoposide has a dual effect on p53: on one hand it favours the 
ubiquitination of BCL6 (that in turn releases its control on p53 and p21157), on the other 
hand it blocks the action of topoisomerase II. This enzyme elicits DNA strand breaks 
that in turn activate p53157,169. 
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In Burkitt’s lymphoma cell lines, for example Ramos cells, etoposide induced a dose-
dependent cell cycle arrest, mostly in  G2, with apoptosis244. We repeated the same 
experiment on SU-DHL4 and Dohh2 cells. Etoposide induced an accumulation of SU-
DHL4 cells in G2 phase (Fig. 26). 
                  
 
 
 
 
 
                  
 
 
 
Figure 26. SU-DHL4 cells exposed to etoposide. Percentage of cells in each phase of 
cell cycle.  
 
 While Dohh2 cells treated with etoposide accumulate in S phase (Fig. 27).  
 
 
 
 
 
 
 
                    
 
Figure 27.  Dohh2  cells exposed to etoposide. Percentage of cells in each phase of 
cell cycle.  
 
Since Dohh2 cells responded to etoposide, known to down regulate BCL6,  and have a 
functional p53250, we decided to test the pathway BCL6-LRF in Dohh2 cells exposed to 
etoposide.  
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2. Dohh2 cells responsiveness to etoposide treatment. 
2.1 Time and dose dependent experiments. 
In order to select the optimal etoposide exposure, we focused on cell proliferation and 
viability. First of all, we exposed exponentially growing Dohh2 cells at increasing 
concentrations (range 0.1-10μM) of etoposide for 16h and we analysed the 
cytotoxicity. 48 hours after the removal of etoposide from the culture medium, cell 
proliferation was reduced in a dose-dependent manner (Fig. 28).  
                        a) 
 
 
 
 
 
 
 
 
                          b) 
 
 
 
 
 
 
 
 
 
Figure 28. Effect of etoposide on proliferation. 48 hours after the removal of 
etoposide from the culture medium proliferation is reduced. a: MTT assay; b: cell 
number. 
 
 
At this point we exposed Dohh2 cells to 10μM etoposide for different times (1h-6h). 
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strongest antiproliferative effects. We  found a progressive reduction of BCL6 
expression (Fig. 29a) and an increase of p53 mRNA  (Fig. 29b) as expected.  
 
a) 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
Figure 29. BCL6 protein and p53 mRNA level in Dohh2 after treatment with 
etoposide. a)Western blot analysis showed a decrease of BCL6 expression from 2 
hours of exposure to etoposide (P=0,0052) and a further protein decrease at 4 
(P=0,0001), 6 (P=0,0002) hours of exposure. The protein levels were calculated as 
reported in Fig.23. b) p53 expression increased after 2 hours of exposure (P=0,0372) to 
etoposide and a further increase at 4 (P=0,0018), 6 (P=0,0001) hours of exposure.  
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Following these experiments we decided to expose Dohh2 cells to a concentration of 
10 μM etoposide for 6 hours. We observed that the exposure to the chemotherapeutic 
agent abolished proliferation of Dohh2 cells (Fig. 30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Cell proliferation of Dohh2 cells treated with etoposide . 
 
In order to test the viability of Dohh2 cells exposed for 6 hours to etoposide, we seeded 
them in methylcellulose. Dishes were incubated at 37° C  in humidified boxes. Five 
days later we observed a dramatic reduction in the colony forming capacity in 
methylcellulose (Fig. 31).  
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         a)                                                             b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Dohh2 capability to form colonies in methylcellulose is influenced by 
etoposide treatment (P = 0,0014): untreated Dohh2 (a) were compared to cells 
exposed to 10 µM of the drug (b). 
 
 
3. BCL6 and LRF response to etoposide treatment. 
Dohh2 cells were exposed to 10 μM etoposide for six hours. The expression of BCL6 
protein was significantly reduced (Fig. 32-a).  
We then analysed the LRF response to etoposide treatment (Fig. 32-b). As for BCL6, 
we observed a significant decrease of LRF although to a lesser extent than that 
observed for BCL6 (Fig. 30). It is possible that the inhibition of cell proliferation 
observed after etoposide is due to the concomitant down-regulation of both oncogenes 
(BCL6 and LRF). A negative feed back loop should link BCL6 and LRF (following the 
interaction showed in the circuit),   while, in etoposide treated cells, these two genes 
showed the same trend. 
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   a) 
 
 
 
 
 
 
 
 
 
 
         b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Western blot and quantification of BCL6 (a) and LRF (b) in Dohh2 
after 6 hours treatment with 10 μM etoposide. The protein levels were normalized as 
reported in Fig. 23. BCL6 and LRF was significantly reduced respectively with a 
P=0,001 and P=0,0008. 
 
3.1 The segment BCL6-p53.  
In order to investigate whether and how BCL6 and LRF were linked, TFs and miRNAs 
potentially involved were considered. It is known that BCL6 acts as a transcriptional 
repressor of p53157. In accordance, we found that the down-regulation of  BCL6 
induced a 70% increase of p53 transcription (Fig. 33). p53 protein level also increased 
by 40% compared with control cells (Fig. 34).  
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Figure 33. Expression of p53 in Dohh2 after 6 hours treatment with 10 μM 
etoposide. p53 mRNA was measured by q-RT-PCR and was normalized to the  value 
found in control cell extracts. Student's t test showed a P value of 0,0025. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Western blot and quantification of p53 in Dohh2 after 6 hours 
treatment with 10 μM etoposide. The protein level was calculated as reported in the 
Fig.23.  
 
We quantified by Real-Time PCR p21 another target of BCL6. We found an increase 
of p21 in the cells treated with etoposide compared with un-treated cells 
(Supplementary Fig.59). p21 transcription could also be activated by the increase of 
p53, given it is one of its targets and we are not able to distinguish between BCL6 or 
p53 action. 
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3.2 The segment p53-miR-145/miR-34a. 
We then determined the level of miR-34a191 and miR-145192, which are reportedly 
controlled by p53 and both target c-Myc. miR-145 was over-expressed, whereas miR-
34a remained unchanged (Fig. 35).  
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Expression level of miR-145 and miR-34a in Dohh2 cells treated with 
etoposide(+) in comparison to untreated cells(-). miR-145 was significantly 
increased with a  P=0,0104. 
 
 
3.3 The segment miR-145-c-Myc. 
miR-145 is considered to be a tumour suppressor  as it  has been shown to negatively 
control the oncogene c-Myc192. Our results are in accordance with this as we observed 
that c-Myc protein was slightly, although significantly reduced by 20 % after etoposide 
treatment (Fig. 36).  
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Figure 36. Western blot and quantification of c-Myc in Dohh2 after 6 hours 
treatment with 10 μM etoposide. The protein level was calculated as reported in the 
Fig. 23. The Student's t test showed a P value of 0,0376. 
 
 
3.4 The segment c-Myc-miR-20a-E2F1.  
c-Myc is involved in a complex feed-back circuit that also includes E2F1 and miR-20a 
(see introduction Fig.16). It has been shown that c-Myc activates the expression of both 
miR-20a as well as E2F1. E2F1 is in turn negatively regulated by miR-20a and 
positively regulates both c-Myc and miR-20a73. 
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Figure 37. Western blot and quantification of E2F1 in Dohh2 after 6 hours 
treatment with 10 μM etoposide. The protein level was calculated as reported in the 
Fig. 23. 
 
 
Given that a positive feed-back loop between c-Myc and E2F1 exists, if c-Myc is 
reduced, E2F1 is expected to decrease, on the contrary we found that E2F1 increases 
(Fig.  37).  
In accordance with this finding, the expression of miR-20a, (controlled by E2F1 see 
Fig .16 introduction) was increased (Fig. 38). 
 
 
 
 
 
 
 
 
 
 
Figure 38. Expression level of miR-20a in Dohh2 cells treated with etoposide in 
comparison to untreated cells. Student's t test showed a P value of 0,0314. 
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It is known that c-Myc negatively controls miR-30 family members, but when we 
evaluated the level of some of them after etoposide a slight down-regulation  was found 
on the contrary to what expected (Supplementary Fig.60). 
 3.5 The segment miR-20a-LRF-p14-miR-28.  
In order to get information on the pathway BCL6-LRF, we evaluated the LRF protein 
after etoposide treatment. In our laboratory it has been demonstrated that miR-20a is 
able to target murine LRF193. We found that etoposide significantly down-regulated 
LRF (Fig. 32-b). Nonetheless at present it is not possible to distinguish whether this 
decrease is caused by an unknown factor or by miR-20a, which increases after 
treatment (Fig. 38). 
To check whether LRF down-regulation has consequences on its downstream targets 
we determined the levels of p14187 and miR-28 251. 
As expected the levels of both miR-28 (Fig. 39) and p14, negatively controlled by LRF, 
were increased (Fig. 40) .  
 
 
 
 
 
 
 
 
 
Figure 39. miR-28 expression level in Dohh2 cells treated with etoposide in 
comparison to untreated cells measured by q-RT-PCR. 
 
 
 
 
 
 
 
Figure 40. p14 expression in Dohh2 after 6 hours treatment with 10 μM etoposide. 
p14 mRNA was measured by q-RT-PCR and was normalized to the corresponding 
control cells value.  
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4. Could miR-145 transfection mimic the effect obtained with 
etoposide treatment? 
 
One of the more interesting results of this analysis is the up-regulation of miR-145 
induced by etoposide. This miRNA has been described as tumour suppressor miRNA. 
Moreover miR-145 has a peculiar position in the circuit: it is positioned in the central 
part of the described pathway linking BCL6 and LRF and lies downstream of two 
important transcription factors BCL6 and p53, and upstream of other miRNAs (miR-
20a) and oncogenes (such as c-Myc, E2F1) implicated in cell proliferation control.  
In order to verify whether the over-expression of miR-145 causes the same effects of 
etoposide treatment, we over-expressed it through transient transfection. This strategy 
could avoid the possible toxic effects due to the etoposide treatment. We transfected 
Dohh2 cells with either negative control (miR-NC) or miR-145 and we measured the 
effects on the BCL6-LRF pathway. In order to bypass the difficulty of transfecting 
Dohh2 cells, we used nucleofection, a particular kind of electroporation. With 
nucleofection the oligo goes into the cell nucleus making the transfection more 
efficient. Cells were harvested 24 hours after nucleofection. The miRNA tested was 
over-expressed by transfecting the mature miRNA (si-miRNA). This is a double-
stranded RNA, a siRNA-like version of miRNA. si-miRNAs offer the advantages that 
they do not need maturation, given that they directly undergo loading into RISC and 
are more protected against RNAses than single stranded molecules. 
The molecules were transiently transfected into Dohh2 cells at a final concentration of 
500 nM. The hypothesis was that over-expression of this miRNA could activate the 
circuit and produce an  antiproliferative effect.  
 
4.1 The segment c-Myc- miR-20a-E2F1. 
In order to verify whether this miR-20a is one of the main actors of this circuit we 
studied the different players of the pathway following after its transfection. Preliminary 
experiments suggest that c-Myc protein level is slightly reduced in Dohh2 cells 
transfected with miR-145 in comparison to cells transfected with miR-NC (Fig. 41).  
 
 
 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Western blot and quantification of c-Myc in Dohh2  24 hours after 
transfection with miR-NC or miR-145. The protein level was calculated as reported 
in the Fig. 23. 
 
 
When we evaluated the expression level of miR-20a, controlled positively by c-Myc no 
significant variation was found, if anything miR-20a was slightly up-regulated (Fig. 
36). However miR-30 family, was up-regulated (Supplementary Fig. 61) suggesting a 
derepression due to c-Myc down-regulation245.  
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Expression of miR-20a in Dohh2 cells 24 hours after the transfection 
with miR-NC or miR-145. 
 
At this point we quantified the level of E2F1, which is involved in the feed-back loop 
between c-Myc and miR-20a. As E2F1 levels also significantly decreased (Fig. 43) we 
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can speculate that in this situation E2F1 and c-Myc may control each other while miR-
20a does not seem to be part of this circuit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. Western blot and quantification of E2F1 in Dohh2 24 hours after the 
transfection of miR-NC or miR-145.The protein level was calculated as reported in 
the Fig. 23. Student's t test showed a P value of 0,0170. 
 
 
4.2 The segment LRF-p14-miR-28. 
LRF expression was unexpectedly influenced by miR-145 over-expression: there was a 
down-regulation of about 35% (Fig. 44), higher than that induced by etoposide 
treatment (Fig. 32-b). 
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Figure 44. Western blot and quantification of LRF in Dohh2 24 hours after the 
transfection of miR-NC or miR-145. The protein level was calculated as reported in 
the Fig. 23. Student's t test showed a P value of 0,0168. 
 
In order to validate the reduction of LRF, we examined the level of the downstream 
members of the circuit: miR-28 and p14. In accordance with LRF reduction both these 
targets were up-regulated. In fact, miR-28 was up-regulated by around 80% (Fig. 45) 
and p14 more than doubled (Fig. 46).  
 
 
 
 
 
 
 
 
 
 
Figure 45. Expression of miR-28 in Dohh2 cells 24 hours after the transfection of 
miR-NC or miR-145. 
 
LRF 
 
Act-b 
miR-NC miR-145
0.00
0.25
0.50
0.75
1.00
L
R
F
 r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
le
v
e
l
*
+ miR-NC + miR-145
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
miR
-28 
rela
tive
exp
res
sion
 lev
el
74 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Expression of p14 in Dohh2 24 hours after the transfection of miR-NC 
or miR-145. p14 mRNA was measured through q-RT-PCR and it was normalized to 
control cell transfected with miR-NC. 
 
 
4.3 p53 does not increase in Dohh2 transiently transfected with miR-145.  
As p14 by blocking the action of MDM2, increases p53 level, we expected p53 up-
regulation after miR-145 over-expression. On the contrary we found a significant 
decrease of p53 (Fig. 47). This decrease was totally unexpected especially since BCL6 
( transcription repressor of p53) appeared also to be down-regulated by about 60% in 
these cells (Fig. 48).  
When we determined the biological effect of miR-145 transfection, we observed that 
the proliferation rate of miR-145 transfected cells did not change in comparison to cells 
transfected with miR-NC (Fig. 49).  
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Figure 47. Western blot and quantification of p53 in Dohh2 24 hours after the 
transfection of miR-NC or miR-145. The protein level was calculated as reported in 
the Fig. 23. Student's t test showed a P value of  0,0428. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48.  Western blot quantification of BCL6 in Dohh2 transfected with miR-
145. The protein level was calculated as reported in the Fig. 23.  Student's t test showed 
a P value of 0,0012. 
 
These results suggest that although the members of the tested circuit were influenced 
by this transfection, their alterations were different, if not opposite, from those induced 
by etoposide, for example p53 and E2F1 were up-regulated in etoposide treated cells 
(Fig. 33-34-37) and down-regulated in transfected cells (Fig. 43-47). The net effect is 
that miR-145 transfection has no proliferative consequence. Also in this treatment 
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BCL6 and LRF showed  a similar trend contrary to what expected: they change their 
expression level in the same direction. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Proliferation rate of Dohh2 cells was not influenced by the transfection 
with either miR-NC (-) or miR-145 (+).  
 
 
Given that the transfection is transient, the increase in miR-145 could be not long 
enough to obtain expected effects.  
 
5. The pathway BCL6-LRF in a clone with stably silenced 
BCL6.  
In order to verify if the BCL6-LRF behaviour of miR-145 transfected cells was due to 
the transient nature of the transfection, we studied a clone in which BCL6 was stably 
silenced and where supposedly p53 should be up-regulated. In our laboratory a plasmid 
expressing si-RNA specific for BCL6 was electroporated in Dohh2 cells. A population 
stably silenced for BCL6 was obtained and we called it BCL6 interference (BCL6i). 
We used electroporation because the Dohh2 cell line was difficult to transfect. It is 
known that this si-RNA is able to degrade BCL6 mRNA. Given that in this construct 
there was a gene encoding for resistance to puromycin, we selected a population 
expressing the si-RNA against BCL6 by growing transfected cells in the presence of 
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this antibiotic. In  this set of experiments the control was Dohh2 cells expressing the 
same vector devoid of the si-RNA sequence called Vector. 
 
 
5.1 Analysis of stably silenced clone. 
In order to verify whether the integration of the construct in the genome of BCL6i cells 
had occurred properly and the plasmid was active, we executed a quantitative Real 
Time PCR analysis and found a 20% reduction of BCL6 mRNA level (Fig. 50-a) as 
well as a 50% reduction of the protein level (Fig. 50-b). 
                     a) 
 
 
 
 
 
 
 
                     b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. BCL6 in Dohh2 stably transfected with sh-RNA (BCL6i), the first 
clone, against BCL6. The mRNA (a) and the protein level (b) were normalized as 
reported in the Fig. 23.    
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5.2 The pathway in BCL6 stably down-regulated Dohh2 cells.  
Given that BCL6 is a transcription repressor, we evaluated the consequences of its 
reduction on one of its principal targets, p53. Compared with cells electroporated with  
an empty plasmid, we found an up-regulation of p53 mRNA of around 40% (Fig. 51).  
 
 
 
 
 
 
 
 
 
 
Figure 51. Real Time PCR quantification of p53 in Dohh2 stably transfected with 
sh-RNA (BCL6i) against BCL6. The mRNA level was normalized to p53 value of 
cells expressing an empty vector (Vector).  
 
Preliminary results indicate that, the up-regulation of p53 mRNA produced an increase 
of p53 protein level (Fig. 52). 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Western blot quantification of p53 in Dohh2 stably transfected with sh-
RNA (BCL6i) against BCL6. The protein level was calculated as reported in the Fig. 
23. 
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Moreover we observed a slight up-regulation of both miR-34a, and miR-145 (Fig. 53), 
whereas the etoposide treatment induced only miR-145 (Fig. 35).  
 
 
 
 
 
 
 
 
 
 
 
Figure 53. Expression level of miR-145 and miR-34a in Dohh2 cells stably 
transfected with sh-RNA (BCL6i) against BCL6. The level of Dohh2 with sh-
RNA(+) was normalized to the value present in cells transfected with an empty vector 
(-) . 
 
 
Our results show that miR-145 up-regulation is followed by down-regulation of c-Myc, 
(Fig. 54).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54. Western blot quantification of c-Myc in Dohh2 stably transfected with 
sh-RNA (BCL6i) against BCL6. The protein level was calculated as reported in the 
Fig. 23. 
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Preliminary results suggest that miR-30 family was slightly up-regulated 
(Supplementary Fig. 62) according with a c-Myc down-regulation.245 
In order to complete the analysis of the circuitry that binds c-Myc- E2F1-miR-20a, we 
quantified the expression level of E2F1 in this clone. Preliminary results indicate that 
both E2F1 (Fig. 55-a) as well as miR-20a levels, are reduced (Fig. 55-b) supporting the 
existence of the circuit c-Myc-E2F1-miR-20a in this clone.  
 
          
  a) 
 
 
 
 
 
 
 
                    
   b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. Quantification of miR-20a (a) and E2F1 (b) in Dohh2 stably transfected 
with sh-RNA (BCL6i) against BCL6. The expression levels were normalized to the 
value in cells expressing an empty vector (Vector). 
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Then we quantified LRF, another component of the pathway. Although in our clone 
miR-20a, one of the miRNAs targeting LRF, was down-regulated the protein level of 
LRF is reduced by around 35% (Fig. 56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56. Western blot and quantification of LRF in Dohh2 stably transfected 
with sh-RNA (BCL6i) against BCL6.The protein level was calculated as reported in 
Fig. 23. 
 
However when two targets of LRF, p14 and miR-28, were evaluated no significant 
change was found suggesting that others experiments need to be done to confirm this 
circuit (Fig. 57).  
 
 
 
 
 
 
 
 
 
Figure 57. Expression level of p14 and miR-28 in Dohh2 cells stably transfected 
with sh-RNA (BCL6i) against BCL6.  
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When we examined whether these changes influenced the proliferation rate of the 
BCL6i clone and the control population, no significant difference was found (Fig. 58).  
 
 
 
 
 
 
 
 
 
 
 
Figure 58. The proliferation rate of Dohh2 cells stably silenced for BCL6 
compared with the control population did not show any differences.  
 
Although the above results represent preliminary analyses that needs to be further 
studied, still they are important because they give us precious information. BCL6 and 
LRF also in the silenced population showed an identical trend. Moreover we could 
observed that these results suggest that a stable increase of miR-145 per se may be not 
sufficient to block cell proliferation in the presence of decreased amounts of E2F1 . 
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1. BCL6 reduction induced p21 after etoposide treatment 
 
 
             
 
 
 
 
 
Figure 59. Expression of p21 in Dohh2 treated with 10 μM etoposide for 6 
hours. p21 mRNA was measured by q-RT-PCR and it was normalized to 
corresponding control cells (P=0,0046) . 
 
 
 2. miR-30 family members after etoposide exposure in Dohh2 
  
 
 
 
 
 
 
 
Figure 60. Expression level of same miR-30 family members in Dohh2 cells 
treated with etoposide (+) in comparison to untreated cells(-).  
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3. miR-30 family members after miR-145 transient transfection  
  
 
 
 
 
 
 
 
 
Figure 61. Expression of miR-30a, miR-30c, miR-30e in Dohh2 cells 24 hours 
after the transfection of miR-NC (-) or miR-145(+). T-student test showed a 
significant increase of miR-30a P value of 0,041. 
 
 
 
4. miR-30 family members in BCL6 stably silenced cells 
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Figure 62. Quantification of miR-30 family members in Dohh2 stably transfected 
with sh-RNA (BCL6i) against BCL6 (+). The expression levels were normalized to 
the value in cells expressing an empty vector (-). 
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5. miRNAs predicted by TargetScan on BCL6 and LRF 
Gene III 
Binding 
sides 
II Binding 
sides 
I Binding side 
LRF miR-
125 
miR-
17.5p , 
miR-302 
miR-99, miR-30.5p, miR-137, miR-148 
BCL6    miR-30.5p, miR-302, miR-17.5p, miR-183, 
miR-34, miR-181, miR-9, miR-205, miR-187, 
miR-375, miR-124, miR-26, miR-10 
 
6. miR-30 and miR-302 target BCL6 3’UTR  
 
 
 
 
 
 
 
 
 
 
 
Figure 63. miR-30c direct interacts with BCL6’s 3’UTR. For each reporter gene 
the relative fluorescence was normalized on value of WT 3’UTR (a). Fluorescence 
was measured 24 hours post transfection into HEK293T. In the figure were reported 
also miRNA’s seed and 3’URT WT and mutated sequences (b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64. miR-302 direct interact with BCL6’s 3’UTR. For each reporter gene 
the relative fluorescence was normalized to value of WT 3’UTR (a). Fluorescence 
was measured 24 hours post transfection into HEK293T. In the figure the miRNA’s 
seed and 3’URT WT and mutated sequences are shown (b). 
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Discussion 
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It was observed that in some types of Non-Hodgkins lymphoma, such as Diffuse large 
B cell (DLBCL) and Follicular lymphoma (FL), there was a simultaneous up-
regulation of the oncogenes BCL6 and LRF156.  We reconstructed a hypothetical circuit 
that links both genes using our data and data taken from the literature demonstrated in 
different model systems. A negative feed back loop should link BCL6 and LRF 
(following the interaction showed in the circuit).  In fact these two genes should have 
an opposite trend: for example a down-regulation of BCL6 should provoke a LRF 
increase, or vice versa, while in Non-Hodgkins lymphomas both these genes are found 
up-regulated. The double increase could be involved in the high proliferation rate 
typical of tumor cells. We hypothesized that the alteration of the correlation between 
BCL6 and LRF could have been developed in lymphoma cells in order to increase their 
proliferation and escape from apoptosis or cell death. In particular we noticed that this 
circuit, which potentially links BCL6 and LRF (see introduction Fig. 16), is formed by 
a series of transcription factors (TFs) and microRNAs (miRNAs) already described as 
involved in tumours, in which cell proliferation is modified. We tried to identify how 
this pathway works in Dohh2 cells and what happened by altering BCL6, one of the 
main player of the pathway . 
We examined the expression value of: 
1. p53,  which is under BCL6 direct  negative control157 and LRF indirect negative 
control156via p14-ARF down-regulation;  
2. miR-34a, which is under p53 positive control191; 
3. miR-145, which is an important link between p53 and c-Myc192, is under p53 
positive control; 
4. c-Myc,  which negatively controls miR-30 family transcription73; 
5. miR-20a, which involved in a complex feed back loop with c-Myc and E2F173;  
6. E2F1, which induces p14-ARF transcription252 thus promoting p53 up-
regulation;  
7. LRF, which is negatively controlled by miR-20a193; 
8. miR-28251 and p14187, which are negatively controlled by LRF.  
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We focused our attention on: Dohh2, a follicular lymphoma, Karpas and SU-DHL4, 
belonging to diffuse large B cell lymphomas. 
Following the quantifications of mRNAs, proteins and miRNAs cited above we 
decided to use the Dohh2 cell line for our experiments because these cells  over-
express both  BCL6 and LRF and have a wild type p53. It is known that etoposide is 
able to down-regulate BCL6244 proteins in Ramos cells. So, with the aim to verify 
whether a correlation between BCL6 and LRF in lymphomas exists and the role of 
miRNAs in the proliferation rate of this disease we reduced BCL6 treating Dohh2 cell 
line with etoposide. We executed time and dose dependence experiments and identified 
10 μM etoposide for six hours as the convenient protocol. The results of the 
experiments are reported in Table n.4.  
In Dohh2 etoposide treatment resulted in a simultaneous decrease of both BCL6 and 
LRF proteins (Fig. 32). This data show that the behavior of these two genes is opposite 
to the expected one (following the interaction showed in the circuit) (see Table n.4 ).   
It is well known that both BCL6157 and LRF187 are transcriptional repressors. To verify 
if their down-regulation influenced other genes, we focused on their target p53. 
Through q-RT-PCR we estimated the mRNA levels and we found that it was up-
regulated in Dohh2 cells treated with etoposide (Fig. 33). We quantified p53 protein 
and verified its increase as well (Fig. 34). The increase of both p53 mRNA and protein 
could have at least three causes. First of all, p53 is under BCL6 negative control. If 
BCL6 is no longer able to execute its task, p53 increases. At the same time, this 
molecule is under LRF indirect control. When LRF decreases, there is an up-regulation 
of  p14 which represses MDM2, that in turn is no longer able to degrade p53. 
Moreover, the chemotherapeutic agent we used induces DNA damages: this is another 
way to activate p53.  
The p53 up-regulation was not only at the protein, but also at the mRNA level, which 
means new transcription of p53. So we could reasonably assert that part of p53 increase 
is due to the down-regulation of both BCL6 and LRF genes.  
It is known that p53 controls the transcription of miR-34a and miR-145. In 
concomitance with p53 increase we found that miR-145 also increased, whereas miR-
34a level was not influence (Fig. 35). This result is very interesting: the etoposide 
treatment did not induced a general up-regulation of the transcription (miR-34a level 
90 
 
did not change) but it was able to selectively activate a pathway rather than another. As 
we determined miR-34a levels 6 hour after treatment, we cannot exclude the possibility 
that its expression level may change at later times.  
Given that miR-145 is described as a tumor suppressor miRNA in many tumor types208, 
its up-regulation, due to etoposide treatment, is intriguing, as it could have a role of 
tumor-suppressor-miRNA also in Dohh2 cells. Moreover, miR-145 is under p53 
control192, hence we would expect that in Dohh2, as in other cell types, miR-145 acts as 
a p53 effector. 
In etoposide treated cells we also found a reduction of c-Myc, one of the targets of 
miR-145 (Fig. 36), and an up-regulation of both miR-20a, controlled by both c-Myc 
(Fig. 38), and E2F1 (Fig. 37). These results were analysed considering the complex 
feed back loop interconnecting c-Myc, miR-20a and E2F1. The up-regulation of E2F1 
could explain the up-regulation of miR-20a level after etoposide treatment, while the 
mechanisms responsible for E2F1 increases are difficult to explain taking into 
consideration only the components of the  described pathway. In fact, given the 
positive control existing between c-Myc and E2F173, an E2F1 reduction due to c-Myc 
decrease was expected. The increase of E2F1 could mean that in Dohh2 cell line this 
double control is not working. Another possible reason of E2F1 increase could be that, 
as a consequence of drug treatment, an unknown factor strongly up regulates E2F1, 
thus overruling the decrease due to c-Myc down regulation. In any case E2F1 and miR-
20a behaviour is different from the expected one. Data present in the literature 
described c-Myc as able to repress the transcription of the miR-30 family members73. 
The analysis of these miRNAs could be interesting because, as showed in 
Supplementary Fig.5, the bioinformatic analysis shows that they have both BCL6 and 
LRF as targets and a preliminary result confirmed that miR-30c is able to bind directly 
BCL6 3’UTR. In Dohh2 cells exposed to etoposide we found a slight down-regulation 
of miR-30 contrary to what expected (Supplementary Fig.60). As previously supposed 
for miR-34a also in this case the variation of miR-30 expression level could be 
connected to the time point that we decided to analyzed: they could be up-regulated in 
a later time.  
In our laboratory it has been demonstrated that miR-20a targets LRF193. The miR-20a 
up-regulation could explain the reduction of LRF protein level observed in Dohh2 cells 
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treated with etoposide (Fig. 32-b). In accordance with LRF down-regulation, two 
targets of LRF, p14187 and miR-28251, were over-expressed in Dohh2 cells treated with 
etoposide (Fig. 39-40). The up-regulation of p14 could be also influenced by the 
increased level of E2F1 that is able to positively influence it. The trend of E2F1, miR-
20a and LRF, even though it is coherent with the relationship existing between them, is 
contrary to  the expected one. 
The consequences of etoposide treatment was a complete block of Dohh2 cells 
proliferation (Fig. 30). Moreover, we found that Dohh2 untreated cells are able to form 
colonies in methycellulose, although with low efficiency, whereas they completely 
loose this capability when subjected to the treatment (Fig. 31). 
From the results obtained with etoposide treatment, we can conclude that in Dohh2 
cells the majority of the segments belonging to BCL6-LRF pathway (see Fig.16 ) 
appear to be active. Nonetheless there are some exceptions. For example, the up-
regulation of p53 is followed by an increase in the transcription of miR-145 but not of 
miR-34a, a tumour suppressor miRNA under p53 control, normally up-regulated after 
DNA damage194,195. Moreover, we found that E2F1 escapes c-Myc control, as reported 
in the literature73, and is  strongly up-regulated by factors not present in the described 
pathway. In the analysis of the pathway a very interesting result is the strong up-
regulation of miR-145 accompanied by p53 and E2F1 increase and block of Dohh2 
cells proliferation.  
The results are schematically summarized in Table n.4. 
Table n.4 Schematic representation of interactions and results of Dohh2 
exposed to etoposide.  
 
 
 
  
 
The rational of the next set of experiments was to verify whether transient over-
expression of the tumour suppressor miR-145 could reproduce the activation of the 
pathway and some of the effects observed in Dohh2 with etoposide treatment. In fact 
miR-145 is positioned in the central part of the described pathway linking BCL6 and 
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LRF. In order to verify the results obtained with etoposide we decided to over-express 
miR-145 in Dohh2 cells through nucleofection and 24 hours after transfection we 
examined the effects on the pathway reported in Fig. 16.  
The results reported in Table n.5 show that c-Myc protein level decreased after miR-
145 transfection (Fig. 41). This down-regulation is confirmed also by the consequent 
up-regulation of the miR-30 family members (Supplementary Fig. 61). Unexpectedly, 
as a consequence of c-Myc down-regulation an up-regulation of miR-20a occurred 
(Fig. 42). This up-regulation is opposite to the expected results and at present we have 
no explanation.  Unlike what we observed in the etoposide treatment, here we found a 
decrease of E2F1 protein level (Fig. 43). A possible reason for this difference could be 
That etoposide treatment and miR-145 may affect different molecular pathways that 
share BCL6.  
In accordance with the miR-20a increase, we found a decrease in LRF protein level 
(Fig. 44) and a consequent up-regulation of p14 and miR-28 (Fig. 45-46). We also 
quantified p53 and BCL6 protein. A p53 increase due to p14 inhibition of MDM2 was 
expected, however we observed that both p53 and BCL6 decrease in Dohh2 cells 
transiently transfected with miR-145 (Fig. 47-48). It is possible that the up-regulation 
of miR-145 activates some other processes that provoke this double reduction. 
The resulting net effect was that miR-145 transfection does not influence cell 
proliferation (Fig. 49). Moreover, also in this treatment BCL6 and LRF showed  a 
similar trend contrary to what expected: they change their expression level in the same 
direction. The main differences between etoposide treatment and miR-145 transfection 
on the target genes were the p53 and E2F1 variations.  
 
Table n.5 Schematic representation of interactions and results of Dohh2 
transfected with miR-145. 
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We could hypothesize three different reasons for these different responses. First of all, 
the down-regulation of c-Myc induced an increase in miR-30 expression level. Indeed, 
these miRNAs , are predicted to target both BCL6 and LRF73. 
Another reason could be that the transient transfection of miR-145 down-regulated both 
proto-oncogenes BCL6 and LRF as well as the tumour suppressors p53. This situation 
could result in a cellular balance between pro-proliferative and anti-proliferative genes 
so that the net proliferation rate is not influenced. 
It is also possible that the transient over-expression of miR-145 may be not sufficiently 
long to cause significant biological effects. 
To test whether a continuous BCL6 down-regulation and consequently a continuous 
miR-145 upregulation,  could provoke different results we took advantage of a Dohh2 
cell line obtained in our laboratory, where BCL6 had been stably silenced through the 
insertion of a construct expressing a siRNA. We called this cells BCL6i. We verified 
the activity of the BCL6 specific siRNA in these cells, quantifying mRNA and protein 
of BCL6 (Fig. 50). The preliminary results are reported in Table n.6. 
First of all, we evaluated the consequences of BCL6 reduction on p53. We found an 
increase of p53 at the mRNA and protein level (Fig. 51-52). The slight up-regulation of 
both miRNAs controlled by p53, miR-145 and miR-34a (Fig. 53), if confirmed, 
indicate that p53 was activated. The increase of miR-34a level confirms indirectly the 
hypothesis that this miRNA needs a longer time to increase than miR-145. Continuing 
on our pathway, we observed a significant decrease in c-Myc protein (Fig. 54) which  
could be due to the combined inhibitory action of miR-145 and miR-34a on this gene. 
Moreover we found, as a preliminary results, a slightly increase in the miR-30 family 
expression level probably due to the down-regulation of c-Myc. As a consequence of c-
Myc variation a  decrease in both miR-20a and E2F1 was found, in accordance with the 
expected results (Fig. 55). Given that both c-Myc and E2F1 positively regulate miR-
20a transcription, their down-regulation could explain miR-20a decrease. 
On the contrary it is difficult to explain, if confirmed, the down-regulation of LRF (Fig. 
56), but this result confirm the previous observation: when BCL6 decreases also LRF 
shows the same trend. It is worth noting that this decrease did not cause an increase of 
miR-28, while it produced a p14 increase ( preliminary results Fig. 57) . 
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Moreover no differences in the proliferation rate of BCL6i cells were found in 
comparison to control cells (Fig. 58). 
These results are preliminary  but we can postulate that during the propagation in 
culture of the BCL6i a population, able to grow even in the presence of lower levels of 
c-Myc and E2F1 and higher levels of p53 and miR-145, could have been selected, 
possibly by altering other cell cycle parameters that we have not investigated.  
 
Table n.6 Schematic representation of interactions and results of Dohh2 
stably silenced for BCL6. 
 
 
 
2. Concluding remarks.  
 
Table n.7 Variations occurring in the circuit following the three 
treatments   
 
 
BCL6 silencing 
 
(Expected 
Results) 
Etoposide 
Treatment 
(Found 
Results) 
miR-145 
over-expression 
(Found 
Results) 
Silenced  
population 
(Found 
Results) 
BCL6 
 
    
p53 
 
    
miR-145 
 
    
c-Myc 
 
    
E2F1 
 
    
miR-20a 
 
    
LRF 
 
    
miR-28 
 
    
p14 
 
    
Proliferation 
 
    
Under 
testing 
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The summary of the three treatments are reported in Table n.7. 
We can affirm that the majority of the segments belonging to BCL6-LRF pathway (see 
Fig.16 ) appear to be active  in Dohh2 cells. Sometimes there are some variations that 
we are not able to explain such as the LRF down-regulation after miR-20a  decrease in 
stably silenced cells. We thus speculate that there are many other unknown molecules 
that are able to interact and influence our pathway. Moreover, we noticed that when we 
altered the expression level of BCL6 (or miR-145) the members of the pathway near 
them respond as expected while farer ones, which respond unexpectedly, could be 
influenced by  factors not present in the described pathway.  
Nonetheless, in three treatments, BCL6 and LRF showed  a similar trend, contrary to 
what expected. This seems to indicate that Dohh2 cells, and probably also other Non-
Hodgkins lymphomas cells, have found a strategy to regulate BCL6 and LRF in the 
same direction. From a biological point of view this could constitute an advantage in 
the proliferation rate and  protect  these cells against apoptosis. In fact only in 
etoposide treatment Dohh2 cells showed a reduction of proliferation while after the 
other two treatments this did not occurred. However these preliminary results suggest 
that down-regulation of both BCL6 and LRF per se is not sufficient to influence the 
proliferation of Dohh2 cells. In fact, only etoposide treatment which activates p53, by 
mechanisms other than LRF and BCL6 down-regulation, and at the same time 
increases E2F1, possibly to apoptotic levels, blocks cell proliferation. If this was the 
case, miR-145 over-expression should be accompanied by the concomitant increase of 
E2F1 (which has a well documented pro-apoptotic action221 ) and p53, in order to 
produce an antiproliferative effect.   
One can speculate that in Dohh2 cells, the links observed between oncogenes such as 
BCL6, LRF, c-Myc and E2F1 and tumour suppressors genes such as p53 and miR-145 
and miR-20a, represent oscillations to maintain an equilibrium among cell cycle 
regulating genes, so that cell proliferation can go on. Another explanation of the 
concomitant down regulation of BCL6 and LRF could be due to the observed up-
regulation of  miR-30. A bioinformatics analysis identified BCL6 and LRF as targets of 
this miRNAs (Supplementary Fig.5). In fact when c-Myc is decreased the transcription 
of these miRNAs increase because they are free from its repression.  
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An unexpected result of this project is the identification of miR-145 as a miRNA that 
(indirectly) down regulates BCL6 and LRF( possibly due to miR-30 up-regulation )  in 
Dohh2, as in every treatment the increase of this miRNA is accompanied by the down-
regulation of the two genes. 
In conclusion although this is only a preliminary research the relationship  found 
between BCL6 and LRF is probably  important for Dohh2 cells to escape apoptosis and 
proliferate. 
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